DXC Technology Co 10-Q for FY2027 Q2
DXC Technology Co (DXC)
10-Q
2026-10-30
For: 2026-09-30
View Original
Added on
October 31, 2026
About this 10-Q
DXC Technology Co filed this 10-Q on October 30, 2026, covering the quarter ended September 30, 2026 (FY2027 Q2).
DXC's second-quarter fiscal 2027 revenue was $3.0 billion, down 4.0% on an organic basis, while EBIT fell to $66 million, down 52.2%. Adjusted EBIT was $187 million, down 26.4%. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $3.03B
- down 4.0% from $3.16B a year earlier
- Net income
- $24M
- down 33.3% from net income of $36M a year earlier
- Diluted EPS
- $0.15
- down 25.0% from $0.20 a year earlier
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |||||
For the quarterly period ended September 30, 2026
OR
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |||||
For the transition period from _____________ to ____________
Commission File No.: 001-38033

| (Exact name of registrant as specified in its charter) | ||
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | ||||||||||||||||||||||
| (Address of principal executive offices and zip code) | |||||||||||||||||||||||
Registrant’s telephone number, including area code: (703 ) 972-7000
| Securities registered pursuant to Section 12(b) of the Act: | |||||||||||||||||||||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | |||||||||||||||||||||
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d)
of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes o No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). x Yes o No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| x | Accelerated Filer | o | ||||||||||||||||||||||||
| Non-accelerated Filer | o | Smaller reporting company | ||||||||||||||||||||||||
| Emerging growth company | ||||||||||||||||||||||||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
TABLE OF CONTENTS
| Item | Page | ||||||||||
| 1. | |||||||||||
| 2. | |||||||||||
| 3. | |||||||||||
| 4. | |||||||||||
| 1. | |||||||||||
| 1A. | |||||||||||
| 2. | |||||||||||
| 3. | |||||||||||
| 4. | |||||||||||
| 5. | |||||||||||
| 6. | |||||||||||
PART I
ITEM 1. FINANCIAL STATEMENTS
Index to Condensed Consolidated Financial Statements
| Page | |||||
1
DXC TECHNOLOGY COMPANY
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||
| (in millions, except per-share amounts) | September 30, 2026 | September 30, 2025 | September 30, 2026 | September 30, 2025 | ||||||||||||||||||||||
| Revenues | $ | $ | $ | $ | ||||||||||||||||||||||
| Costs of services (excludes depreciation and amortization and restructuring costs) | ||||||||||||||||||||||||||
| Selling, general and administrative (excludes depreciation and amortization and restructuring costs) | ||||||||||||||||||||||||||
| Depreciation and amortization | ||||||||||||||||||||||||||
| Restructuring costs | ||||||||||||||||||||||||||
| Interest expense | ||||||||||||||||||||||||||
| Interest income | ( | ( | ( | ( | ||||||||||||||||||||||
| Other income, net | ( | ( | ( | ( | ||||||||||||||||||||||
| Total costs and expenses | ||||||||||||||||||||||||||
| Income before income taxes | ||||||||||||||||||||||||||
| Income tax expense | ||||||||||||||||||||||||||
| Net income | ||||||||||||||||||||||||||
| Less: net (loss) income attributable to non-controlling interest, net of tax | ( | ( | ||||||||||||||||||||||||
| Net income attributable to DXC common stockholders | $ | $ | $ | $ | ||||||||||||||||||||||
Income per common share: | ||||||||||||||||||||||||||
| Basic | $ | $ | $ | $ | ||||||||||||||||||||||
| Diluted | $ | $ | $ | $ | ||||||||||||||||||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
2
DXC TECHNOLOGY COMPANY
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (unaudited)
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||||||||
| (in millions) | September 30, 2026 | September 30, 2025 | September 30, 2026 | September 30, 2025 | ||||||||||||||||||||||||||||
Net income | $ | $ | $ | $ | ||||||||||||||||||||||||||||
| Other comprehensive income (loss), net of taxes: | ||||||||||||||||||||||||||||||||
Foreign currency translation adjustments, net of tax (1) | ( | ( | ||||||||||||||||||||||||||||||
Cash flow hedges adjustments, net of tax (2) | ( | ( | ||||||||||||||||||||||||||||||
| Pension and other post-retirement benefit plans, net of tax: | ||||||||||||||||||||||||||||||||
Amortization of prior service cost, net of tax (3) | ( | ( | ( | |||||||||||||||||||||||||||||
| Pension and other post-retirement benefit plans, net of tax | ( | ( | ( | |||||||||||||||||||||||||||||
| Other comprehensive income (loss), net of taxes | ( | ( | ||||||||||||||||||||||||||||||
| Comprehensive income (loss) | ( | ( | ||||||||||||||||||||||||||||||
| Less: comprehensive (loss) income attributable to non-controlling interest | ( | ( | ||||||||||||||||||||||||||||||
| Comprehensive income (loss) attributable to DXC common stockholders | $ | $ | ( | $ | $ | ( | ||||||||||||||||||||||||||
______________
(1) Tax expense (benefit) related to foreign currency translation adjustments was $1 and $2 for the three and six months ended September 30, 2026, respectively, and $0 and $(15 ) for the three and six months ended September 30, 2025, respectively.
(2) Tax expense (benefit) related to cash flow hedges adjustments was $1 and $4 for the three and six months ended September 30, 2026, respectively, and $(2 ) and $(4 ) for the three and six months ended September 30, 2025, respectively.
(3) Tax expense related to amortization of prior service costs was $0 and $0 for the three and six months ended September 30, 2026, respectively, and $0 and $0 for the three and six months ended September 30, 2025, respectively.
The accompanying notes are an integral part of these condensed consolidated financial statements.
3
DXC TECHNOLOGY COMPANY
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)
| As of | ||||||||||||||
| (in millions, except per-share and share amounts) | September 30, 2026 | March 31, 2026 | ||||||||||||
| ASSETS | ||||||||||||||
| Current assets: | ||||||||||||||
| Cash and cash equivalents | $ | $ | ||||||||||||
Receivables and contract assets, net of allowance of $ | ||||||||||||||
| Prepaid expenses | ||||||||||||||
| Other current assets | ||||||||||||||
| Total current assets | ||||||||||||||
Intangible assets, net of accumulated amortization of $ | ||||||||||||||
| Operating right-of-use assets, net | ||||||||||||||
| Goodwill | ||||||||||||||
| Deferred income taxes, net | ||||||||||||||
Property and equipment, net of accumulated depreciation of $ | ||||||||||||||
| Other assets | ||||||||||||||
| Total Assets | $ | $ | ||||||||||||
| LIABILITIES and EQUITY | ||||||||||||||
| Current liabilities: | ||||||||||||||
| Short-term debt and current maturities of long-term debt | ||||||||||||||
| Accounts payable | ||||||||||||||
| Accrued payroll and related costs | ||||||||||||||
| Current operating lease liabilities | ||||||||||||||
| Accrued expenses and other current liabilities | ||||||||||||||
| Deferred revenue and advance contract payments | ||||||||||||||
| Income taxes payable | ||||||||||||||
| Total current liabilities | ||||||||||||||
| Long-term debt, net of current maturities | ||||||||||||||
| Non-current deferred revenue | ||||||||||||||
| Non-current operating lease liabilities | ||||||||||||||
| Non-current income tax liabilities and deferred tax liabilities | ||||||||||||||
| Other long-term liabilities | ||||||||||||||
| Total Liabilities | ||||||||||||||
| Commitments and contingencies | ||||||||||||||
| DXC stockholders’ equity: | ||||||||||||||
Preferred stock, par value $ | ||||||||||||||
Common stock, par value $ | ||||||||||||||
| Additional paid-in capital | ||||||||||||||
| Accumulated deficit | ( | ( | ||||||||||||
| Accumulated other comprehensive loss | ( | ( | ||||||||||||
Treasury stock, at cost, | ( | ( | ||||||||||||
| Total DXC stockholders’ equity | ||||||||||||||
| Non-controlling interest in subsidiaries | ||||||||||||||
| Total Equity | ||||||||||||||
| Total Liabilities and Equity | $ | $ | ||||||||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
4
DXC TECHNOLOGY COMPANY
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)
| Six Months Ended | ||||||||||||||
| (in millions) | September 30, 2026 | September 30, 2025 | ||||||||||||
| Cash flows from operating activities: | ||||||||||||||
| Net income | $ | $ | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||||
| Depreciation and amortization | ||||||||||||||
| Goodwill impairment losses | ||||||||||||||
| Operating right-of-use expense | ||||||||||||||
| Share-based compensation | ||||||||||||||
| Deferred taxes | ||||||||||||||
| Loss (gain) on dispositions | ( | |||||||||||||
| Provision for losses on accounts receivable | ||||||||||||||
| Unrealized foreign currency exchange gain | ( | ( | ||||||||||||
| Impairment losses and contract write-offs | ||||||||||||||
| Other non-cash charges, net | ( | ( | ||||||||||||
| Changes in assets and liabilities: | ||||||||||||||
| Decrease in assets | ||||||||||||||
| Decrease in operating lease liability | ( | ( | ||||||||||||
| Decrease in other liabilities | ( | ( | ||||||||||||
| Net cash provided by operating activities | ||||||||||||||
| Cash flows from investing activities: | ||||||||||||||
| Purchases of property and equipment | ( | ( | ||||||||||||
| Payments for transition and transformation contract costs | ( | ( | ||||||||||||
| Software purchased and developed | ( | ( | ||||||||||||
| Proceeds from sale of assets | ||||||||||||||
| Other investing activities, net | ||||||||||||||
| Net cash used in investing activities | ( | ( | ||||||||||||
| Cash flows from financing activities: | ||||||||||||||
| Principal payments on long-term debt | ( | |||||||||||||
| Payments on finance leases and borrowings for asset financing | ( | ( | ||||||||||||
| Taxes paid related to net share settlements of share-based compensation awards | ( | ( | ||||||||||||
| Repurchase of common stock | ( | ( | ||||||||||||
| Other financing activities, net | ( | ( | ||||||||||||
| Net cash used in financing activities | ( | ( | ||||||||||||
| Effect of exchange rate changes on cash and cash equivalents | ( | |||||||||||||
| Net (decrease) increase in cash and cash equivalents | ( | |||||||||||||
| Cash and cash equivalents at beginning of year | ||||||||||||||
| Cash and cash equivalents at end of period | $ | $ | ||||||||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
5
DXC TECHNOLOGY COMPANY
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (unaudited)
| Three Months Ended September 30, 2026 | ||||||||||||||||||||||||||||||||
| (in millions, except shares in thousands) | Common Stock | Additional Paid-in Capital | Accumulated Deficit | Accumulated Other Comprehensive Loss | Treasury Stock(1) | Total DXC Equity | Non- Controlling Interest | Total Equity | ||||||||||||||||||||||||
| Shares | Amount | |||||||||||||||||||||||||||||||
| Balance at June 30, 2026 | $ | $ | $ | ( | $ | ( | $ | ( | $ | $ | $ | |||||||||||||||||||||
| Net Income | ( | |||||||||||||||||||||||||||||||
| Other comprehensive income | ||||||||||||||||||||||||||||||||
| Share-based compensation expense | ||||||||||||||||||||||||||||||||
| Acquisition of treasury stock | ( | ( | ( | |||||||||||||||||||||||||||||
| Share repurchase program | ( | ( | ( | ( | ||||||||||||||||||||||||||||
| Stock option exercises and other common stock transactions | — | — | ||||||||||||||||||||||||||||||
| Balance at September 30, 2026 | $ | $ | $ | ( | $ | ( | $ | ( | $ | $ | $ | |||||||||||||||||||||
| Three Months Ended September 30, 2025 | ||||||||||||||||||||||||||||||||
| (in millions, except shares in thousands) | Common Stock | Additional Paid-in Capital | Accumulated Deficit | Accumulated Other Comprehensive Loss | Treasury Stock | Total DXC Equity | Non- Controlling Interest | Total Equity | ||||||||||||||||||||||||
| Shares | Amount | |||||||||||||||||||||||||||||||
| Balance at June 30, 2025 | $ | $ | $ | ( | $ | ( | $ | ( | $ | $ | $ | |||||||||||||||||||||
Net income | ||||||||||||||||||||||||||||||||
| Other comprehensive loss | ( | ( | ( | ( | ||||||||||||||||||||||||||||
| Share-based compensation expense | ||||||||||||||||||||||||||||||||
| Acquisition of treasury stock | ( | ( | ( | |||||||||||||||||||||||||||||
| Share repurchase program | ( | ( | ( | ( | ||||||||||||||||||||||||||||
| Stock option exercises and other common stock transactions | — | — | ||||||||||||||||||||||||||||||
| Balance at September 30, 2025 | $ | $ | $ | ( | $ | ( | $ | ( | $ | $ | $ | |||||||||||||||||||||
6
| Six Months Ended September 30, 2026 | ||||||||||||||||||||||||||||||||
| (in millions, except shares in thousands) | Common Stock | Additional Paid-in Capital | Accumulated Deficit | Accumulated Other Comprehensive Loss | Treasury Stock(1) | Total DXC Equity | Non- Controlling Interest | Total Equity | ||||||||||||||||||||||||
| Shares | Amount | |||||||||||||||||||||||||||||||
| Balance at March 31, 2026 | $ | $ | $ | ( | $ | ( | $ | ( | $ | $ | $ | |||||||||||||||||||||
| Net income | ( | |||||||||||||||||||||||||||||||
| Other comprehensive income | ||||||||||||||||||||||||||||||||
| Share-based compensation expense | ||||||||||||||||||||||||||||||||
| Acquisition of treasury stock | ( | ( | ( | |||||||||||||||||||||||||||||
| Share repurchase program | ( | ( | ( | ( | ||||||||||||||||||||||||||||
| Stock option exercises and other common stock transactions | — | — | ||||||||||||||||||||||||||||||
| Balance at September 30, 2026 | $ | $ | $ | ( | $ | ( | $ | ( | $ | $ | $ | |||||||||||||||||||||
| Six Months Ended September 30, 2025 | ||||||||||||||||||||||||||||||||
| (in millions, except shares in thousands) | Common Stock | Additional Paid-in Capital | Accumulated Deficit | Accumulated Other Comprehensive Loss | Treasury Stock | Total DXC Equity | Non- Controlling Interest | Total Equity | ||||||||||||||||||||||||
| Shares | Amount | |||||||||||||||||||||||||||||||
| Balance at March 31, 2025 | $ | $ | $ | ( | $ | ( | $ | ( | $ | $ | $ | |||||||||||||||||||||
| Net income | ||||||||||||||||||||||||||||||||
| Other comprehensive loss | ( | ( | ( | ( | ||||||||||||||||||||||||||||
| Share-based compensation expense | ||||||||||||||||||||||||||||||||
| Acquisition of treasury stock | ( | ( | ( | |||||||||||||||||||||||||||||
| Share repurchase program | ( | ( | ( | ( | ||||||||||||||||||||||||||||
| Stock option exercises and other common stock transactions | — | — | ||||||||||||||||||||||||||||||
| Non-controlling interest distributions and other | — | — | ( | ( | ||||||||||||||||||||||||||||
| Balance at September 30, 2025 | $ | $ | $ | ( | $ | ( | $ | ( | $ | $ | $ | |||||||||||||||||||||
_____________
The accompanying notes are an integral part of these condensed consolidated financial statements.
7
DXC TECHNOLOGY COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
Note 1 – Summary of Significant Accounting Policies
Business
DXC Technology Company (“DXC,” the “Company,” “we,” “us,” or “our”) is a leading enterprise technology and innovation partner delivering software, services, and solutions to global enterprises and public sector organizations — helping them harness AI to drive outcomes at a time of exponential change with speed. With deep expertise in Managed Infrastructure Services, Application Modernization, and Industry-Specific Software Solutions, DXC modernizes, secures, and operates some of the world’s most complex technology estates.
Segment Structure
The Company’s three reportable segments align with how management assesses performance of the business and allocates resources: Consulting & Engineering Services ("CES"), Global Infrastructure Services ("GIS"), and Insurance Software & Services ("Insurance"). Across these segments, we embed AI, automation and data-driven capabilities into our solutions to improve efficiency, enhance operations and support better business outcomes for clients. See Note 16 - "Segment Information" for more information. Descriptions for each segment are provided below:
•Consulting & Engineering Services – Helps businesses use AI and data analytics to improve operations, automate tasks, and speed up their digital transformation. We provide software engineering, consulting, and custom and enterprise applications solutions that help companies manage essential functions, modernize processes, and drive innovation. We have strong expertise in industries like finance, automotive, manufacturing, healthcare, life sciences, travel, and the public sector. Our solutions help businesses stay competitive by improving efficiency, launching new products faster, expanding into new markets, and achieving their strategic goals.
•Global Infrastructure Services – Implements and operates the technology underpinning the critical systems of global businesses and governments. Clients trust us to secure, modernize, and operate their critical systems and improve workplace experience to support business growth. Services include the design, migration, and management of complex data center, mainframe, cloud, and network environments, with an emphasis on scalability, security, compliance, and cost efficiency. By leveraging a human-led, AI-driven Intelligent Operations approach, we deliver secure, reliable IT operations that clients trust. We also provide cross-industry business process services, which streamline clients’ core enterprise functions such as finance, HR, procurement, and customer service. The implementation of secure, reliable technology improves employee experiences and productivity by streamlining daily operations—such as device management, helpdesk support, and AI-powered automation—enabling seamless collaboration, reducing IT support demands, and lowering costs through intuitive, self-service tools.
•Insurance Software & Services – Provides software and services for Life and Wealth, Property & Casualty and Reinsurance providers, helping them optimize, run and digitally transform their operations. We help insurers modernize their technology landscape from heritage systems to advanced AI-powered solutions that enhance operational efficiency, improve customer experiences, and enable insurers to adopt a digital-first approach. Complementing our software solutions, we provide comprehensive business process services, leveraging deep industry expertise to support the full spectrum of insurance operations.
Basis of Presentation
In order to make this report easier to read, DXC refers throughout to (i) the interim unaudited Condensed Consolidated Financial Statements as the “financial statements,” (ii) the Condensed Consolidated Statements of Operations as the “statements of operations,” (iii) the Condensed Consolidated Statements of Comprehensive Income (Loss) as the “statements of comprehensive income,” (iv) the Condensed Consolidated Balance Sheets as the “balance sheets,” and (v) the Condensed Consolidated Statements of Cash Flows as the “statements of cash flows.” In addition, references are made throughout to the numbered Notes to the Condensed Consolidated Financial Statements (“Notes”) in this Quarterly Report on Form 10-Q.
8
DXC TECHNOLOGY COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
The accompanying financial statements include the accounts of DXC, its consolidated subsidiaries, and those business entities in which DXC maintains a controlling interest. Investments in business entities in which the Company does not have control, but has the ability to exercise significant influence over operating and financial policies, are accounted for by the equity method. Other investments are accounted for by the cost method. Non-controlling interests are presented as a separate component within equity in the balance sheets. Net earnings attributable to the non-controlling interests are presented separately in the statements of operations and comprehensive income attributable to non-controlling interests are presented separately in the statements of comprehensive income. All intercompany transactions and balances have been eliminated.
The financial statements of the Company have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) for quarterly reports and accounting principles generally accepted in the United States (“GAAP”). Certain disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules. These financial statements should therefore be read in conjunction with the audited consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2026 (“fiscal 2026”).
Use of Estimates
Recent Accounting Pronouncements
The following Accounting Standards Updates (“ASU”) issued by the Financial Accounting Standards Board have not yet been adopted by DXC:
| Date Issued and ASU | DXC Effective Date | Description | Impact | ||||||||
| November 2024 ASU 2024-03, “Disaggregation of Income Statement Expenses” | Fiscal 2028 | The update requires disclosure, in the notes to financial statements, of specified quantitative information about certain costs and expenses presented in the income statement and certain qualitative information about costs that are not disaggregated. Early adoption of this update is permitted. | The Company is in the process of assessing the impacts and method of adoption. This ASU will impact the Company’s financial statement disclosures, but not its consolidated financial statements. | ||||||||
September 2025 ASU 2025-06, “Targeted Improvements to the Accounting for Internal-Use Software” | Fiscal 2029 | The update amends the guidance for capitalizing internal-use software so that it is neutral to different software development methods, primarily by removing the previous “development stage” model to more closely align the capitalization of internal use software to that of software to be sold or marketed externally. Early adoption of this update is permitted. | The Company is in the process of assessing the impact of the ASU on our consolidated financial statements as well as its method of adoption. | ||||||||
Other recently issued ASUs that have not yet been adopted are not expected to have a material effect on DXC’s condensed consolidated financial statements.
9
DXC TECHNOLOGY COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
Note 2 – Earnings per Share
Basic earnings per share (“EPS”) is computed using the weighted average number of shares of common stock outstanding during the period. Diluted EPS reflects the incremental shares issuable upon the assumed exercise of stock options and equity awards. The following table reflects the calculation of basic and diluted EPS:
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||
| (in millions, except per-share amounts) | September 30, 2026 | September 30, 2025 | September 30, 2026 | September 30, 2025 | ||||||||||||||||||||||
Net income attributable to DXC common shareholders: | $ | $ | $ | $ | ||||||||||||||||||||||
| Common share information: | ||||||||||||||||||||||||||
| Weighted average common shares outstanding for basic EPS | ||||||||||||||||||||||||||
| Dilutive effect of stock options and equity awards | ||||||||||||||||||||||||||
| Weighted average common shares outstanding for diluted EPS | ||||||||||||||||||||||||||
| Earnings per share: | ||||||||||||||||||||||||||
| Basic | $ | $ | $ | $ | ||||||||||||||||||||||
| Diluted | $ | $ | $ | $ | ||||||||||||||||||||||
Certain share-based equity awards were excluded from the dilutive EPS calculation because they would have an anti-dilutive effect. The number of awards excluded were as follows:
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||
| September 30, 2026 | September 30, 2025 | September 30, 2026 | September 30, 2025 | |||||||||||||||||||||||
| Stock Options | ||||||||||||||||||||||||||
| Restricted Stock Units | ||||||||||||||||||||||||||
| Performance Stock Units | ||||||||||||||||||||||||||
10
DXC TECHNOLOGY COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
Note 3 – Receivables
Allowance for Doubtful Accounts
The following table presents the change in balance for the allowance for doubtful accounts:
| As of | ||||||||||||||
| (in millions) | September 30, 2026 | September 30, 2025 | ||||||||||||
| Beginning balance | $ | $ | ||||||||||||
| Provisions for losses on accounts receivable | ||||||||||||||
| Other adjustments to allowance and write-offs | ( | ( | ||||||||||||
| Ending balance | $ | $ | ||||||||||||
Receivables Facility
The Company has an accounts receivable sales facility (as amended, restated, supplemented or otherwise modified, the “Receivables Facility”) with certain unaffiliated financial institutions (the “Purchasers”) for the sale of commercial accounts receivable in the United States up to a maximum amount of $400 million. The Receivables Facility was amended on July 24, 2026, extending the termination date to July 23, 2027.
As of September 30, 2026, the total availability under the Receivables Facility was $400 million and the amount sold to the Purchasers was $397 million, which was derecognized from the Company’s balance sheet. As of September 30, 2026, the Company recorded a $3 million asset within accounts receivable because the amount of cash proceeds received by the Company under the Receivables Facility was less than the total availability.
The fair value of the sold receivables approximated book value due to the short-term nature, and as a result, no gain or loss on sale of receivables was recorded.
Note 4 – Leases
The Company has operating and finance leases for data centers, corporate offices, and certain equipment. Its leases have remaining lease terms of to nine years , some of which include options to extend the leases for up to ten years , and some of which include options to terminate the leases within to three years .
Operating Leases
The components of operating lease expense were as follows:
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||
| (in millions) | September 30, 2026 | September 30, 2025 | September 30, 2026 | September 30, 2025 | ||||||||||||||||||||||
| Operating lease cost | $ | $ | $ | $ | ||||||||||||||||||||||
| Short-term lease cost | ||||||||||||||||||||||||||
| Variable lease cost | ||||||||||||||||||||||||||
| Sublease income | ( | ( | ( | ( | ||||||||||||||||||||||
| Total operating costs | $ | $ | $ | $ | ||||||||||||||||||||||
11
DXC TECHNOLOGY COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
Cash payments made for variable lease costs and short-term leases are not included in the measurement of operating lease liabilities, and as such, are excluded from the supplemental cash flow information below.
| Six Months Ended | ||||||||||||||
| (in millions) | September 30, 2026 | September 30, 2025 | ||||||||||||
Cash paid for amounts included in the measurement of operating lease liabilities – operating cash flows | $ | $ | ||||||||||||
ROU assets obtained in exchange for operating lease liabilities(1) | $ | $ | ||||||||||||
_______________
(1) Net of $208 million and $406 million in lease modifications and terminations during the first six months of fiscal 2027 and 2026, respectively. See Note 15 – “Cash Flows” for further information on non-cash activities affecting cash flows.
The following table presents operating lease balances:
| As of | ||||||||||||||||||||
| (in millions) | Balance Sheet Line Item | September 30, 2026 | March 31, 2026 | |||||||||||||||||
| ROU operating lease assets | Operating right-of-use assets, net | $ | $ | |||||||||||||||||
| Operating lease liabilities | Current operating lease liabilities | $ | $ | |||||||||||||||||
| Operating lease liabilities | Non-current operating lease liabilities | |||||||||||||||||||
| Total operating lease liabilities | $ | $ | ||||||||||||||||||
The weighted-average operating lease term was 3.4 years and 3.7 years as of September 30, 2026 and March 31, 2026, respectively. The weighted-average operating lease discount rate was 4.8 % and 4.9 % as of September 30, 2026 and March 31, 2026, respectively.
The following maturity analysis presents expected undiscounted cash payments for operating leases as of September 30, 2026:
Fiscal Year | ||||||||||||||||||||||||||||||||||||||||||||
(in millions) | Remainder of 2027 | 2028 | 2029 | 2030 | 2031 | Thereafter | Total | |||||||||||||||||||||||||||||||||||||
Operating lease payments | $ | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||||||||||||
Less: imputed interest | ( | |||||||||||||||||||||||||||||||||||||||||||
Total operating lease liabilities | $ | |||||||||||||||||||||||||||||||||||||||||||
12
DXC TECHNOLOGY COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
Finance Leases
The components of finance lease expense were as follows:
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||
| (in millions) | September 30, 2026 | September 30, 2025 | September 30, 2026 | September 30, 2025 | ||||||||||||||||||||||
| Amortization of right-of-use assets | $ | $ | $ | $ | ||||||||||||||||||||||
| Interest on lease liabilities | ||||||||||||||||||||||||||
| Total finance lease expense | $ | $ | $ | $ | ||||||||||||||||||||||
The following table provides supplemental cash flow information related to the Company’s finance leases:
| Six Months Ended | ||||||||||||||
| (in millions) | September 30, 2026 | September 30, 2025 | ||||||||||||
Interest paid for finance lease liabilities – Operating cash flows | $ | $ | ||||||||||||
Cash paid for amounts included in the measurement of finance lease obligations – financing cash flows | ||||||||||||||
| Total cash paid in the measurement of finance lease obligations | $ | $ | ||||||||||||
Capital expenditures through finance lease obligations(1) | $ | $ | ||||||||||||
_____________
(1) See Note 15 – ”Cash Flows” for further information on non-cash activities affecting cash flows.
The following table presents finance lease balances:
| As of | ||||||||||||||||||||
| (in millions) | Balance Sheet Line Item | September 30, 2026 | March 31, 2026 | |||||||||||||||||
| ROU finance lease assets | $ | $ | ||||||||||||||||||
| Finance lease | $ | $ | ||||||||||||||||||
| Finance lease | ||||||||||||||||||||
Total finance lease liabilities(1) | $ | $ | ||||||||||||||||||
_____________
(1) See Note 8 – “Debt” for further information on finance lease liabilities.
The weighted-average finance lease term was 2.2 years and 2.3 years as of September 30, 2026 and March 31, 2026, respectively. The weighted-average finance lease discount rate was 6.1 % and 6.0 % as of September 30, 2026 and March 31, 2026, respectively.
The following maturity analysis presents expected undiscounted cash payments for finance leases as of September 30, 2026:
Fiscal Year | ||||||||||||||||||||||||||||||||||||||||||||
(in millions) | Remainder of 2027 | 2028 | 2029 | 2030 | 2031 | Thereafter | Total | |||||||||||||||||||||||||||||||||||||
Finance lease payments | $ | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||||||||||||
Less: imputed interest | ( | |||||||||||||||||||||||||||||||||||||||||||
Total finance lease liabilities | $ | |||||||||||||||||||||||||||||||||||||||||||
13
DXC TECHNOLOGY COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
Note 5 – Derivative Instruments
In the normal course of business, the Company is exposed to interest rate and foreign exchange rate fluctuations. As part of its risk management strategy, the Company uses derivative instruments, primarily foreign currency forward contracts and interest rate swaps, to hedge certain foreign currency and interest rate exposures. The Company’s objective is to reduce earnings volatility by offsetting gains and losses resulting from these exposures with losses and gains on the derivative contracts used to hedge them. The Company does not use derivative instruments for trading or any speculative purposes.
Derivatives Designated for Hedge Accounting
Cash flow hedges
The Company has designated certain foreign currency forward contracts as cash flow hedges to reduce foreign currency risk related to certain Indian Rupee-denominated obligations and forecasted transactions. The notional amounts of foreign currency forward contracts designated as cash flow hedges as of September 30, 2026 and March 31, 2026 were $41 million and $197 million, respectively. As of September 30, 2026, the related forecasted transactions extend through December 2026.
During the six months ended September 30, 2026 and September 30, 2025, respectively, the Company had no cash flow hedges for which it was probable that the hedged transaction would not occur.
See Note 13 - “Stockholders’ Equity” for changes in accumulated other comprehensive loss, net of taxes, related to the Company’s derivatives designated for hedge accounting. As of September 30, 2026, $3 million of loss related to cash flow hedges reported in accumulated other comprehensive loss is expected to be reclassified into earnings within the next 12 months.
Derivatives Not Designated for Hedge Accounting
The derivative instruments not designated as hedges for purposes of hedge accounting include certain short-term foreign currency forward contracts. Derivatives that are not designated as hedging instruments are adjusted to fair value through earnings in the financial statement line item to which the derivative relates.
Foreign currency forward contracts
The Company manages the exposure to fluctuations in foreign currencies by using primarily short-term foreign currency forward contracts to hedge certain foreign currency denominated assets and liabilities, including intercompany accounts and forecasted transactions. The net notional amounts of the foreign currency forward contracts outstanding as of September 30, 2026 and March 31, 2026 were $1.1 billion and $1.3 billion, respectively.
14
DXC TECHNOLOGY COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
The following table presents the foreign currency (gain) loss to Other income, net:
Three Months Ended | Six Months Ended | |||||||||||||||||||||||||||||||
| (in millions) | September 30, 2026 | September 30, 2025 | September 30, 2026 | September 30, 2025 | ||||||||||||||||||||||||||||
Foreign currency remeasurement (1) | $ | ( | $ | $ | $ | ( | ||||||||||||||||||||||||||
Undesignated foreign currency forward contracts (2) | ( | ( | ||||||||||||||||||||||||||||||
Total - Foreign currency (gain) loss | $ | $ | ( | $ | $ | ( | ||||||||||||||||||||||||||
_____________
(1) Movements from exchange rates on the Company’s foreign currency-denominated assets and liabilities.
(2) Movements from hedges used to manage the Company’s foreign currency remeasurement exposure, and the associated costs of the hedging program.
Other Risks for Derivative Instruments
The Company is exposed to the risk of losses in the event of non-performance by the counterparties to its derivative contracts. The amount subject to credit risk related to derivative instruments is generally limited to the amount, if any, by which a counterparty’s obligations exceed the obligations of the Company with that counterparty. To mitigate counterparty credit risk, the Company regularly reviews its credit exposure and the creditworthiness of the counterparties. With respect to its foreign currency derivatives, as of September 30, 2026, there were two counterparties with concentration of credit risk, and based on gross fair value, the maximum amount of loss that the Company could incur is $2 million.
The Company also enters into enforceable master netting arrangements with some of its counterparties. However, for financial reporting purposes, it is the Company’s policy not to offset derivative assets and liabilities despite the existence of enforceable master netting arrangements. The potential effect of such netting arrangements on the Company’s balance sheets is not material for the periods presented.
Non-Derivative Financial Instruments Designated for Hedge Accounting
The Company applies hedge accounting for foreign currency-denominated intercompany debt used to manage foreign currency exposures on its net investments in certain non-U.S. operations. To qualify for hedge accounting, the hedging instrument must be highly effective at reducing the risk from the exposure being hedged.
Net Investment Hedges
DXC seeks to reduce the impact of fluctuations in foreign exchange rates on its net investments in certain non-U.S. operations with foreign currency-denominated intercompany debt. For foreign currency-denominated intercompany debt designated as a hedge, the effectiveness of the hedge is assessed based on changes in spot rates. For qualifying net investment hedges, all gains or losses on the hedging instruments are included in currency translation. Gains or losses on individual net investments in non-U.S. operations are reclassified to earnings from accumulated other comprehensive income (loss) when such net investments are sold or substantially liquidated.
15
DXC TECHNOLOGY COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
Note 6 – Intangible Assets
Intangible assets consisted of the following:
| As of September 30, 2026 | As of March 31, 2026 | |||||||||||||||||||||||||||||||||||||
| (in millions) | Gross Carrying Value | Accumulated Amortization | Net Carrying Value | Gross Carrying Value | Accumulated Amortization | Net Carrying Value | ||||||||||||||||||||||||||||||||
| Software | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||||
Customer related intangible assets | ||||||||||||||||||||||||||||||||||||||
Other intangible assets | ||||||||||||||||||||||||||||||||||||||
| Total intangible assets | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||||
The components of amortization expense were as follows:
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||
| (in millions) | September 30, 2026 | September 30, 2025 | September 30, 2026 | September 30, 2025 | ||||||||||||||||||||||
| Intangible asset amortization | $ | $ | $ | $ | ||||||||||||||||||||||
Transition and transformation contract cost amortization(1) | ||||||||||||||||||||||||||
| Total amortization expense | $ | $ | $ | $ | ||||||||||||||||||||||
_____________
(1)Transaction and transformation contract costs are included within other assets on the balance sheets. The balance within other assets is $513 million and $577 million as of September 30, 2026 and March 31, 2026, respectively.
Estimated future amortization related to intangible assets as of September 30, 2026 is as follows:
| Fiscal Year | (in millions) | |||||||
| Remainder of 2027 | $ | |||||||
| 2028 | ||||||||
| 2029 | ||||||||
| 2030 | ||||||||
| 2031 | ||||||||
| Thereafter | ||||||||
| Total | $ | |||||||
16
DXC TECHNOLOGY COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
Note 7 – Goodwill
The following table summarizes the changes in the carrying amount of goodwill, by segment, for the six months ended September 30, 2026.
| (in millions) | Consulting & Engineering Services | Global Infrastructure Services | Insurance Services | Total | ||||||||||||||||||||||
| Balance as of March 31, 2026, net | $ | $ | $ | $ | ||||||||||||||||||||||
Foreign currency translation(1) | ||||||||||||||||||||||||||
| Balance as of September 30, 2026, net | $ | $ | $ | $ | ||||||||||||||||||||||
| Goodwill, gross | ||||||||||||||||||||||||||
| Accumulated impairment losses | ( | ( | ( | ( | ||||||||||||||||||||||
| Balance as of September 30, 2026, net | $ | $ | $ | $ | ||||||||||||||||||||||
_____________
(1) The foreign currency translation amount reflects the impact of currency movements on non-U.S. dollar-denominated goodwill balances.
Goodwill Impairment Analysis
The Company tests goodwill for impairment on an annual basis, as of the first day of the second fiscal quarter, and between annual tests if circumstances change, or if an event occurs that would more likely than not reduce the fair value of a reporting unit below its carrying amount.
For the Company’s annual goodwill impairment assessment as of July 1, 2026, the Company chose the option to bypass the initial qualitative assessment stage and proceed directly to the quantitative goodwill impairment test. The test concluded that the fair value of the Company’s CES and Insurance reporting units exceeded their respective carrying amounts. The goodwill balances for CES and Insurance were not impaired.
As part of the test, the quantitative analysis for the CES reporting unit, which holds goodwill of $378 million as of July 1, 2026, showed that fair value exceeded carrying value by 13 %. In the event that there is a significant unfavorable change to the revenue growth rates included in the forecasted cash flows as well as terminal value of the reporting unit used in the fair value estimates, we may be required to record an impairment of goodwill at a future date.
As of September 30, 2026, the Company assessed whether there were events or changes in circumstances that would more likely than not reduce the fair value of any of its reporting units below its carrying amount and require goodwill to be tested for impairment. The Company determined that there have been no such indicators and therefore, it was unnecessary to perform an interim goodwill impairment test as of September 30, 2026.
17
DXC TECHNOLOGY COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
Note 8 – Debt
The following is a summary of the Company’s debt:
| (in millions) | Interest Rates | Fiscal Year Maturities | September 30, 2026(1) | March 31, 2026(1) | |||||||||||||||||||||||||||||||||||||
| Short-term debt and current maturities of long-term debt | |||||||||||||||||||||||||||||||||||||||||
$ | 2027 | ||||||||||||||||||||||||||||||||||||||||
€ | 2028 | ||||||||||||||||||||||||||||||||||||||||
| Current maturities of finance lease liabilities | 2027 - 2028 | ||||||||||||||||||||||||||||||||||||||||
| Current maturities of other long-term debt | Various | 2027 - 2028 | |||||||||||||||||||||||||||||||||||||||
| Short-term debt and current maturities of long-term debt | $ | $ | |||||||||||||||||||||||||||||||||||||||
| Long-term debt, net of current maturities | |||||||||||||||||||||||||||||||||||||||||
€ | 2028 | ||||||||||||||||||||||||||||||||||||||||
$ | 2029 | ||||||||||||||||||||||||||||||||||||||||
€ | 2031 | ||||||||||||||||||||||||||||||||||||||||
€ | 2032 | ||||||||||||||||||||||||||||||||||||||||
| Finance lease liabilities | 2027 - 2035 | ||||||||||||||||||||||||||||||||||||||||
| Borrowings for assets acquired under long-term financing | 2027 - 2033 | ||||||||||||||||||||||||||||||||||||||||
| Other borrowings | Various | 2027 - 2035 | |||||||||||||||||||||||||||||||||||||||
| Long-term debt, net of current maturities | |||||||||||||||||||||||||||||||||||||||||
Total debt | $ | $ | |||||||||||||||||||||||||||||||||||||||
_____________
Fair Value of Debt
The estimated fair value of the Company’s senior notes was $2.7 billion and $3.1 billion as of September 30, 2026 and March 31, 2026, respectively, compared with a carrying value of $2.9 billion and $3.3 billion, respectively. Senior notes are classified as Level 2 within the fair value hierarchy.
Revolving Credit Facility
As of September 30, 2026, the Company's total liquidity was $4.6 billion, consisting of $1.6 billion of cash and cash equivalents and $3.0 billion of available borrowings under our revolving credit facility, with no borrowings outstanding under the facility at any time during the fiscal year.
18
DXC TECHNOLOGY COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
Note 9 – Revenue
Revenue Recognition
The following table presents DXC’s revenues disaggregated by geography, based on the location of incorporation of the DXC entity providing the related goods or services:
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||
| (in millions) | September 30, 2026 | September 30, 2025 | September 30, 2026 | September 30, 2025 | ||||||||||||||||||||||
| United States | $ | $ | $ | $ | ||||||||||||||||||||||
| United Kingdom | ||||||||||||||||||||||||||
| Other Europe | ||||||||||||||||||||||||||
| Australia | ||||||||||||||||||||||||||
| Other International | ||||||||||||||||||||||||||
| Total Revenues | $ | $ | $ | $ | ||||||||||||||||||||||
The revenue by geography pertains to all of the Company’s reportable segments. Refer to Note 16 – “Segment Information” for the Company’s segment disclosures.
Remaining Performance Obligations
As of September 30, 2026, approximately $15.8 billion of revenue is expected to be recognized from remaining performance obligations. We expect to recognize revenue on approximately 25 % of these remaining performance obligations in fiscal 2027, with the remainder of the balance recognized thereafter.
Contract Balances
The following table provides information about the balances of the Company’s trade receivables, contract assets, and contract liabilities:
| As of | ||||||||||||||||||||
| (in millions) | Balance Sheet Line Item | September 30, 2026 | March 31, 2026 | |||||||||||||||||
| Trade receivables, net | Receivables and contract assets, net of allowance for doubtful accounts | $ | $ | |||||||||||||||||
| Contract assets | Receivables and contract assets, net of allowance for doubtful accounts | $ | $ | |||||||||||||||||
| Contract liabilities | Deferred revenue and advance contract payments and Non-current deferred revenue | $ | $ | |||||||||||||||||
Changes in contract liabilities were as follows:
| Six Months Ended | ||||||||||||||
| (in millions) | September 30, 2026 | September 30, 2025 | ||||||||||||
| Balance, beginning of period | $ | $ | ||||||||||||
| Deferred revenue | ||||||||||||||
| Recognition of deferred revenue | ( | ( | ||||||||||||
| Currency translation adjustment | ||||||||||||||
| Other | ( | ( | ||||||||||||
| Balance, end of period | $ | $ | ||||||||||||
19
DXC TECHNOLOGY COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
Note 10 – Restructuring Costs
The composition of restructuring liabilities by financial statement line items is as follows:
| As of | ||||||||||||||||||||
| (in millions) | September 30, 2026 | March 31, 2026 | ||||||||||||||||||
| Accrued expenses and other current liabilities | $ | $ | ||||||||||||||||||
| Other long-term liabilities | ||||||||||||||||||||
| Total | $ | $ | ||||||||||||||||||
Summary of Restructuring Plans
Fiscal 2027 Plan
During fiscal 2027, management approved global cost savings initiatives designed to better align the Company’s workforce, facility and data center requirements (the “Fiscal 2027 Plan”).
Restructuring Liability Reconciliations by Plan
| Restructuring Liability as of March 31, 2026 | Costs Expensed, Net of Reversals | Costs Not Affecting Restructuring Liability(1) | Cash Paid | Other(2) | Restructuring Liability as of September 30, 2026 | |||||||||||||||||||||||||||||||||
| Fiscal 2027 Plan | ||||||||||||||||||||||||||||||||||||||
| Workforce Reductions | $ | $ | $ | $ | ( | $ | $ | |||||||||||||||||||||||||||||||
| Facilities Costs | ( | |||||||||||||||||||||||||||||||||||||
| ( | ( | |||||||||||||||||||||||||||||||||||||
| Fiscal 2026 Plan | ||||||||||||||||||||||||||||||||||||||
| Workforce Reductions | $ | $ | $ | $ | ( | $ | $ | |||||||||||||||||||||||||||||||
| Facilities Costs | ( | |||||||||||||||||||||||||||||||||||||
| ( | ( | |||||||||||||||||||||||||||||||||||||
| Other Prior Year and Acquired Plans | ||||||||||||||||||||||||||||||||||||||
| Workforce Reductions | $ | $ | $ | $ | ( | $ | $ | |||||||||||||||||||||||||||||||
| Facilities Costs | ( | ( | ( | |||||||||||||||||||||||||||||||||||
| ( | ( | ( | ||||||||||||||||||||||||||||||||||||
| Total | $ | $ | $ | ( | $ | ( | $ | $ | ||||||||||||||||||||||||||||||
_____________
(1) Restructuring costs associated with right-of-use assets.
(2) Foreign currency translation adjustments.
Included in restructuring costs for the six months of fiscal 2027 is $2 million related to amortization of the right-of-use asset and interest expense for leased facilities that have been vacated but are being actively marketed for sublease or we are in negotiations with the landlord to potentially terminate or modify those leases.
20
DXC TECHNOLOGY COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
Note 11 – Pension and Other Benefit Plans
Defined Benefit Plans
The components of net periodic pension income were:
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||||||||||||||||||||
| (in millions) | September 30, 2026 | September 30, 2025 | September 30, 2026 | September 30, 2025 | ||||||||||||||||||||||||||||||||||||||||
| Service cost | $ | $ | $ | $ | ||||||||||||||||||||||||||||||||||||||||
| Interest cost | ||||||||||||||||||||||||||||||||||||||||||||
| Expected return on assets | ( | ( | ( | ( | ||||||||||||||||||||||||||||||||||||||||
| Amortization of prior service costs | ( | ( | ( | ( | ||||||||||||||||||||||||||||||||||||||||
| Net periodic pension income | $ | ( | $ | ( | $ | ( | $ | ( | ||||||||||||||||||||||||||||||||||||
The service cost component of net periodic pension income is presented in costs of services and selling, general and administrative and the other components of net periodic pension income are presented in Other income, net.
Note 12 – Income Taxes
The Company’s effective tax rate (“ETR”) was 75.9 % and 69.5 % for the three months ended September 30, 2026, and September 30, 2025, respectively, and 52.9 % and 70.7 % for the six months ended September 30, 2026, and September 30, 2025, respectively. For the three months ended September 30, 2026, the primary drivers of the ETR were the global mix of income, and U.S. tax on foreign income. For the six months ended September 30, 2026, the primary drivers of the ETR were the global mix of income, U.S. tax on foreign income, and a decrease in a deferred tax asset for stock based compensation. For the three months ended September 30, 2025, the primary drivers of the ETR were the global mix of income, U.S. tax on foreign income, and the tax benefit of a worthless stock deduction under section 165(g) of the Internal Revenue Code related to the Company's investment in a wholly owned subsidiary. For the six months ended September 30, 2025, the primary drivers of the ETR were the global mix of income, U.S. tax on foreign income, the tax benefit of a worthless stock deduction under section 165(g) of the Internal Revenue Code related to the Company’s investment in a wholly owned subsidiary, and a decrease in a deferred tax asset for stock based compensation.
As of September 30, 2026, the Company had undistributed earnings from foreign subsidiaries that were not indefinitely reinvested and had a deferred tax liability of $19 million for the estimated taxes associated with the repatriation of these earnings. The Company also had undistributed earnings and other outside basis differences in foreign subsidiaries that were indefinitely reinvested for which no taxes have been provided and the quantification of the deferred tax liability, if any, was not practicable. If future events, including material changes in estimates of cash, working capital and long-term investment requirements, necessitate that these earnings be distributed, an additional provision for taxes may apply, which could materially affect our future effective tax rate.
In connection with the merger of Computer Sciences Corporation (“CSC”) and the Enterprise Services business of Hewlett Packard Enterprise Company (the “HPES Merger”), the Company entered into a tax matters agreement with Hewlett Packard Enterprise Company (“HPE”). HPE generally will be responsible for tax liabilities arising prior to the HPES Merger, and DXC is liable to HPE for income tax receivables it receives related to pre-HPES Merger periods. Pursuant to the tax matters agreement, the Company recorded a $14 million tax indemnification receivable related to uncertain tax positions, a $25 million tax indemnification receivable related to other tax payables, and a $91 million tax indemnification payable related to other tax receivables.
21
DXC TECHNOLOGY COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
In connection with the spin-off of the Company’s former U.S. public sector business (the “USPS Separation”), the Company entered into a tax matters agreement with Perspecta Inc. (including its successors and permitted assigns, “Perspecta”). The Company generally will be responsible for tax liabilities arising prior to the USPS Separation, and Perspecta is liable to the Company for income tax receivables related to pre-spin-off periods. Income tax liabilities transferred to Perspecta primarily relate to pre-HPES Merger periods, for which the Company is indemnified by HPE pursuant to the tax matters agreement between the Company and HPE. The Company remains liable to HPE for tax receivables transferred to Perspecta related to pre-HPES Merger periods. Pursuant to the tax matters agreement, the Company recorded a $12 million tax indemnification receivable from Perspecta related to other tax receivables.
In connection with the sale of its healthcare provider software business (“HPS”), the Company entered into a tax matters agreement with Dedalus. Pursuant to the tax matters agreement, the Company generally will be responsible for tax liabilities arising prior to the sale of the HPS business.
The Internal Revenue Service (the “IRS”) has examined, or is examining, the Company’s federal income tax returns for fiscal years 2009 through 2021. With respect to CSC’s fiscal years 2009 through 2017 federal tax returns, the Company participated in settlement negotiations with the IRS Office of Appeals. The IRS examined several issues for these tax years that resulted in various audit adjustments. The Company and the IRS Office of Appeals have settled various audit adjustments, and we disagree with the IRS’ disallowance of certain losses and deductions resulting from restructuring costs, foreign exchange losses, and a third-party financing transaction in previous years.
We have received notices of deficiency and a final partnership administrative adjustment with respect to fiscal years 2009, 2010, 2011 and 2013 and have timely filed petitions with the U.S. Tax Court.
The U.S. Tax Court cases generally involve three primary issues. The first issue pertains to a capital loss the Company claimed in fiscal year 2013 in the amount of $651 million, which the IRS subsequently disallowed, and for which it proposed a substantial understatement penalty. The total cash tax payment the IRS is seeking is approximately $520 million, inclusive of penalties and interest, which continues to accrue. The U.S. Tax Court held a trial on this matter in two sessions in August and October 2025. Post-trial briefing concluded in April 2026. A decision from the court is now pending.
The second issue pertains to the Company’s deduction for restructuring expenses in fiscal year 2013 in the amount of $139 million, which the IRS has disputed. The total cash tax payment the IRS is seeking is approximately $111 million, inclusive of penalties and interest, which continues to accrue. In January 2025, the Court denied the IRS’ motion for summary judgment. This issue is set for trial in November 2027.
The third issue primarily pertains to foreign currency losses from 2009 that the Company claimed in fiscal years 2010 and 2011 in the amount of $163 million, resulting from the depreciation of the U.S. dollar against the Euro over an eight-year period (from 2001 to 2009) upon termination of a partnership interest involving two entities with different functional currencies. The total cash tax payment the IRS is seeking is approximately $129 million, inclusive of penalties and interest. In March 2026, the Court granted the IRS’ motion for summary judgment. In June 2026, the Company’s motion for reconsideration was denied. In August 2026, the Company made a deposit of approximately $122 million of tax and estimated interest with the IRS under Section 6603 of the Internal Revenue Code to suspend the accrual of further interest on most of the IRS’ claim. A final decision on the Company’s tax liability is pending.
As we believe we will ultimately prevail on the technical merits of the first and second issues above and are continuing to challenge them in the U.S. Tax Court, the first and second issues are not fully reserved and would result in incremental federal and state tax expense of approximately $537 million (including estimated interest and penalties) for the unreserved portion of these items, if we do not prevail. The total cash tax exposure across all three issues above is approximately $551 million after taking into account the Section 6603 deposit and net of an expected $87 million interest deduction tax benefit.
During fiscal 2024, the Company determined there were inadvertent omissions on previously filed tax returns related to gain recognition agreements and certain related tax forms and disclosures. The Company notified the IRS promptly and filed for relief under Treas. Reg. Sec. 1.367(a)-8(p) to correct the issue.
22
DXC TECHNOLOGY COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
The Company’s fiscal years 2009, 2010, and 2013 are in the U.S. Tax Court, and consequently these years will remain open until such proceedings have concluded. The Company has agreed to extend the statute of limitations for fiscal and tax return years 2014 through 2021 to December 31, 2027. The Company expects to reach resolution for fiscal and tax return years 2009 through 2011 no earlier than fiscal year 2027. The Company expects to reach resolution for fiscal and tax return years 2012 and 2013 no earlier than fiscal year 2029. The Company expects to reach resolution for fiscal and tax return years 2014 through 2021 no earlier than fiscal year 2028.
23
DXC TECHNOLOGY COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
Note 13 – Stockholders’ Equity
Share Repurchase Program
Share repurchase activity for the first six months of fiscal 2027 and fiscal 2026 was as follows:
| Fiscal 2027 | Fiscal 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fiscal Period | Number of Shares Repurchased | Average Price Per Share | Amount (in millions) | Number of Shares Repurchased | Average Price Per Share | Amount (in millions) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 1st Quarter | $ | $ | $ | $ | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2nd Quarter | $ | $ | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | $ | $ | $ | $ | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Loss
The following table shows the changes in accumulated other comprehensive loss, net of taxes:
| (in millions) | Foreign Currency Translation Adjustments | Cash Flow Hedges | Pension and Other Post-retirement Benefit Plans | Accumulated Other Comprehensive Loss | ||||||||||||||||||||||||||||
| Balance at March 31, 2026 | $ | ( | $ | ( | $ | $ | ( | |||||||||||||||||||||||||
Other comprehensive income before reclassifications | ( | |||||||||||||||||||||||||||||||
| Amounts reclassified from accumulated other comprehensive loss | ( | |||||||||||||||||||||||||||||||
| Balance at September 30, 2026 | $ | ( | $ | ( | $ | $ | ( | |||||||||||||||||||||||||
| (in millions) | Foreign Currency Translation Adjustments | Cash Flow Hedges | Pension and Other Post-retirement Benefit Plans | Accumulated Other Comprehensive Loss | ||||||||||||||||||||||
| Balance at March 31, 2025 | $ | ( | $ | ( | $ | $ | ( | |||||||||||||||||||
| Other comprehensive loss before reclassifications | ( | ( | ( | |||||||||||||||||||||||
| Amounts reclassified from accumulated other comprehensive loss | ( | |||||||||||||||||||||||||
| Balance at September 30, 2025 | $ | ( | $ | ( | $ | $ | ( | |||||||||||||||||||
24
DXC TECHNOLOGY COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
Note 14 – Stock Incentive Plans
Restricted Stock Units and Performance-Based Restricted Stock Units
Restricted stock units (“RSUs”) represent the right to receive one share of DXC common stock upon a future settlement date, subject to vesting and other terms and conditions of the award, plus any dividend equivalents accrued during the award period.
The RSUs vest one-third ratably over a three-year period. In general, if the employees’ status as a full-time employee is terminated prior to the vesting of the RSU grant in full, then the RSU grant is automatically canceled on the termination date and any unvested shares and dividend equivalents are forfeited.
The Company also grants performance-based restricted stock units (“PSUs”), which generally vest at the end of a three-year period. The number of PSUs that ultimately vest is dependent upon the Company’s achievement of certain specified financial performance criteria over a three-year period. If the specified performance criteria are met, awards are settled for shares of DXC common stock and dividend equivalents shortly subsequent to the end of the performance period, subject to continued employment through the last day of the third fiscal year. DXC also issued PSU awards that are considered to have a market condition. Settlement of shares for these PSU awards will be made shortly subsequent to the end of the third fiscal year, subject to certain market conditions and continued employment through the last day of the third fiscal year.
The fair value of RSUs and PSUs is based on the Company’s common stock closing price on the grant date. For PSUs with a market-based condition, DXC uses a Monte Carlo simulation model to value the grants.
| Employee Equity Plan | Director Equity Plan | |||||||||||||||||||||||||
| Number of Shares | Weighted Average Grant Date Fair Value | Number of Shares | Weighted Average Grant Date Fair Value | |||||||||||||||||||||||
| Outstanding as of March 31, 2026 | $ | $ | ||||||||||||||||||||||||
| Granted | $ | $ | ||||||||||||||||||||||||
| Settled | ( | $ | ( | $ | ||||||||||||||||||||||
| Canceled/Forfeited | ( | $ | $ | |||||||||||||||||||||||
| Outstanding as of September 30, 2026 | $ | $ | ||||||||||||||||||||||||
Share-Based Compensation
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||||||||||||||
| (in millions) | September 30, 2026 | September 30, 2025 | September 30, 2026 | September 30, 2025 | ||||||||||||||||||||||||||||||||||
| Total share-based compensation cost | $ | $ | $ | $ | ||||||||||||||||||||||||||||||||||
| Related income tax benefit | $ | $ | $ | $ | ||||||||||||||||||||||||||||||||||
25
DXC TECHNOLOGY COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
Note 15 – Cash Flows
Cash payments for interest on indebtedness and income taxes and other select non-cash activities are as follows:
| Six Months Ended | ||||||||||||||
| (in millions) | September 30, 2026 | September 30, 2025 | ||||||||||||
| Cash paid for: | ||||||||||||||
| Interest | $ | $ | ||||||||||||
Taxes on income, net of refunds (1) | $ | $ | ||||||||||||
| Non-cash activities: | ||||||||||||||
| Operating: | ||||||||||||||
ROU assets obtained in exchange for lease, net (2) | $ | $ | ||||||||||||
| Investing: | ||||||||||||||
Capital expenditures in accounts payable and accrued expenses (3) | $ | $ | ||||||||||||
| Capital expenditures through finance lease obligations | $ | $ | ||||||||||||
| Assets acquired under long-term financing | $ | $ | ||||||||||||
| Financing: | ||||||||||||||
| Shares repurchased but not settled in cash | $ | $ | ||||||||||||
_____________
(1) Income tax refunds were $17 million and $35 million for the six months ended September 30, 2026 and September 30, 2025, respectively.
(2) Net of $208 million and $406 million in lease modifications and terminations during the first six months of fiscal 2027 and 2026, respectively.
(3) Accrued expenses includes both short-term and long-term liabilities.
26
DXC TECHNOLOGY COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
Note 16 – Segment Information
DXC has a matrix form of organization and is managed in several different and overlapping groupings including services, industries and geographic regions. As a result, and in accordance with accounting standards, operating segments are organized by the type of services provided. Our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”) serve as our Chief Operating Decision Makers ("CODM") and are responsible for obtaining, reviewing, and managing the Company’s financial performance based on these segments.
The Company reports its financial results under a segment structure designed to reflect the Company’s operational structure and the delivery of end-to-end IT services. The structure includes three reportable segments that align with how management assesses performance of the business and allocates resources: CES, GIS, and Insurance, as previously described above in Note 1 - “Summary of Significant Accounting Policies.” In connection with our segment reporting change, we have recast previously reported amounts across all reportable segments to conform to current segment presentation.
The Company's CODM uses segment profit to measure operational strength and performance, assist in evaluation of underlying trends, and allocate resources through periodic budget and forecasting processes. Segment profit is defined as segment revenues less costs of services, selling, general and administrative, depreciation and amortization, and other segment items.
The Company allocates certain costs such as real estate costs, information technology costs and costs for certain other shared corporate functions to its segments using a proportional share of either revenue or headcount for each segment. The Company does not allocate to its segments certain operating expenses managed at the corporate level. These unallocated expenses generally include certain corporate function costs, pension and other post-retirement benefit (“OPEB”) actuarial and settlement gains and losses, restructuring costs, transaction, separation, and integration-related costs, amortization of acquired intangible assets, impairment losses, gains/(losses) on dispositions of businesses, gains/(losses) on real estate and facility sales, and other costs that do not reflect ongoing segment operating performance. As part of the transition to the new segment structure, the Company updated the assumptions that define which expenses remain in corporate post allocation. The tables below reflect those revised assumptions.
27
DXC TECHNOLOGY COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
Segment Measures
The following table summarizes operating results regularly provided to the CODM by reportable segment and a reconciliation to the financial statements:
| (in millions) | CES | GIS | Insurance | Total Reportable Segments | ||||||||||||||||||||||
| Three Months Ended September 30, 2026 | ||||||||||||||||||||||||||
| Revenues | $ | $ | $ | $ | ||||||||||||||||||||||
Costs of services | ( | ( | ( | ( | ||||||||||||||||||||||
Selling, general and administrative | ( | ( | ( | ( | ||||||||||||||||||||||
Depreciation and amortization(1) | ( | ( | ( | ( | ||||||||||||||||||||||
Other segment items(2) | ||||||||||||||||||||||||||
| Segment profit | $ | $ | $ | $ | ||||||||||||||||||||||
| Three Months Ended September 30, 2025 | ||||||||||||||||||||||||||
| Revenues | $ | $ | $ | $ | ||||||||||||||||||||||
Costs of services | ( | ( | ( | ( | ||||||||||||||||||||||
Selling, general and administrative | ( | ( | ( | ( | ||||||||||||||||||||||
Depreciation and amortization(1) | ( | ( | ( | ( | ||||||||||||||||||||||
Other segment items(2) | ||||||||||||||||||||||||||
| Segment profit | $ | $ | $ | $ | ||||||||||||||||||||||
| (in millions) | CES | GIS | Insurance | Total Reportable Segments | ||||||||||||||||||||||
| Six Months Ended September 30, 2026 | ||||||||||||||||||||||||||
| Revenues | $ | $ | $ | $ | ||||||||||||||||||||||
Costs of services | ( | ( | ( | ( | ||||||||||||||||||||||
Selling, general and administrative | ( | ( | ( | ( | ||||||||||||||||||||||
Depreciation and amortization(1) | ( | ( | ( | ( | ||||||||||||||||||||||
Other segment items(2) | ||||||||||||||||||||||||||
| Segment profit | $ | $ | $ | $ | ||||||||||||||||||||||
| Six Months Ended September 30, 2025 | ||||||||||||||||||||||||||
| Revenues | $ | $ | $ | $ | ||||||||||||||||||||||
Costs of services | ( | ( | ( | ( | ||||||||||||||||||||||
Selling, general and administrative | ( | ( | ( | ( | ||||||||||||||||||||||
Depreciation and amortization(1) | ( | ( | ( | ( | ||||||||||||||||||||||
Other segment items(2) | ||||||||||||||||||||||||||
| Segment profit | $ | $ | $ | $ | ||||||||||||||||||||||
_____________
(1) Depreciation and amortization as presented excludes amortization of acquired intangible assets.
(2) Other segment items as presented include non-service cost components of net periodic pension income and other miscellaneous segment gains/(losses).
28
DXC TECHNOLOGY COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
Reconciliation of Reportable Segment Profit to Consolidated Total
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||
| (in millions) | September 30, 2026 | September 30, 2025 | September 30, 2026 | September 30, 2025 | ||||||||||||||||||||||
| Total profit for reportable segments | $ | $ | $ | $ | ||||||||||||||||||||||
Corporate expenses | ( | ( | ( | ( | ||||||||||||||||||||||
Subtotal | $ | $ | $ | $ | ||||||||||||||||||||||
| Restructuring costs | ( | ( | ( | ( | ||||||||||||||||||||||
| Transaction, separation and integration-related costs | ( | ( | ( | ( | ||||||||||||||||||||||
| Amortization of acquired intangible assets | ( | ( | ( | ( | ||||||||||||||||||||||
| Merger related indemnification | ( | |||||||||||||||||||||||||
| Gain on litigation award | ||||||||||||||||||||||||||
| (Losses) gains on real estate, facility sales and dispositions | ( | ( | ||||||||||||||||||||||||
| Impairment losses | ( | |||||||||||||||||||||||||
| Interest income | ||||||||||||||||||||||||||
Interest expense | ( | ( | ( | ( | ||||||||||||||||||||||
| Income before income taxes | $ | $ | $ | $ | ||||||||||||||||||||||
Management does not use total assets by segment to evaluate segment performance or allocate resources. As a result, assets are not tracked by segment and therefore, total assets by segment are not disclosed.
Note 17 – Other Liabilities
The following table provides the components of other liabilities:
| As of | ||||||||||||||
| (in millions) | September 30, 2026 | March 31, 2026 | ||||||||||||
| Accrued Expenses and Other Current Liabilities | ||||||||||||||
| Indirect tax expenses | $ | $ | ||||||||||||
Employee-related obligations(1) | ||||||||||||||
Operating expenses and other current liabilities(2) | ||||||||||||||
| Total | $ | $ | ||||||||||||
| Other Long-term Liabilities | ||||||||||||||
| Indemnification obligations | $ | $ | ||||||||||||
Employee-related obligations(1) | ||||||||||||||
Operating expenses and other long-term liabilities(2) | ||||||||||||||
| Total | $ | $ | ||||||||||||
___________________________
(1) Includes the Company’s pension obligations and other certain employee-related obligations.
(2) Includes multi-year third-party software license agreements and accrued services for professional service providers and other vendors primarily related to program-level activities.
29
DXC TECHNOLOGY COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
Note 18 – Commitments and Contingencies
Commitments
Minimum purchase commitments as of September 30, 2026 were as follows:
| Fiscal year | Minimum Purchase Commitment | |||||||
| (in millions) | ||||||||
| Remainder of 2027 | $ | |||||||
| 2028 | ||||||||
| 2029 | ||||||||
| 2030 | ||||||||
| 2031 | ||||||||
| Thereafter | ||||||||
| Total | $ | |||||||
Contingencies
Tax Examinations: The Company is under IRS examination in the U.S. on its federal income tax returns for certain fiscal years and is in disagreement with the IRS on certain tax positions, which are currently being contested in the U.S. Tax Court. For more detail, see Note 12 – “Income Taxes.”
In addition to the matters noted above, the Company is currently subject in the normal course of business to various claims and contingencies arising from, among other things, disputes with customers, vendors, employees, contract counterparties and other parties, as well as securities matters, environmental matters, matters concerning the licensing and use of intellectual property, and inquiries and investigations by regulatory authorities and government agencies. Some of these disputes involve or may involve litigation. The financial statements reflect the treatment of claims and contingencies based on management’s view of the expected outcome. DXC consults with outside legal counsel on issues related to litigation and regulatory compliance and seeks input from other experts and advisors with respect to matters in the ordinary course of business. Although the outcome of these and other matters cannot be predicted with certainty, and the impact of the final resolution of these and other matters on the Company’s results of operations in a particular subsequent reporting period could be material and adverse, management does not believe based on information currently available to the Company, that the resolution of any of the matters currently pending against the Company will have a material adverse effect on the financial position of the Company or the ability of the Company to meet its financial obligations as they become due. Unless otherwise noted, the Company is unable to determine at this time a reasonable estimate of a possible loss or range of losses associated with the foregoing disclosed contingent matters.
30
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
All statements and assumptions contained in this Quarterly Report on Form 10-Q and in the documents incorporated by reference that do not directly and exclusively relate to historical facts constitute “forward-looking statements” that involve numerous assumptions, risks and uncertainties. Forward-looking statements often include words such as “anticipates,” “believes,” “estimates,” “expects,” “forecast,” “goal,” “intends,” “objective,” “plans,” “projects,” “strategy,” “target,” and “will” and words and terms of similar substance in discussions of future operating or financial performance.
We may also make forward-looking statements in other reports filed with the Securities and Exchange Commission (“SEC”), in materials delivered to stockholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements. Forward-looking statements represent current expectations and beliefs, and no assurance can be given that the results, goals or plans described in such statements can or will be achieved, and readers are cautioned not to place undue reliance on such statements, which speak only as of the date they are made. We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date of this report or to reflect the occurrence of unanticipated events, except as required by law.
Forward-looking statements include, among other things, statements with respect to our future financial condition, results of operations, cash flows, business strategies, operating efficiencies or synergies, restructuring plans, potential acquisitions and divestitures, competitive position, growth opportunities, artificial intelligence and technology initiatives, effective tax rates, liquidity and capital resources, capital return strategy, plans and objectives of management, the outcome of and costs associated with regulatory and litigation matters, and other matters.
Important factors that could cause actual results to differ materially from those described in forward-looking statements, many of which are outside of our control, include, but are not limited to:
•our inability to effectively manage and improve our sales organization, including structural challenges related to sales execution, pipeline development, and talent management;
•our inability to develop and expand our service offerings to address emerging business demands and technological trends, and the competitive pressures faced by our business;
•our inability to attract and retain key personnel, including sales talent and employees with artificial intelligence and technical expertise, and to maintain relationships with key partners;
•risks associated with AI, including our adoption, deployment, and governance of AI technologies, reliance on third-party AI platforms, AI-related cybersecurity and data privacy risks, evolving AI regulations, and competitive displacement from AI;
•our inability to accurately estimate the cost of services and the timeline for completion of contracts, or if we or third parties fail to deliver on commitments or otherwise breach obligations to our customers;
•systems failures, catastrophic events, and resulting interruptions in the availability of our products or services;
•the risk of liability, reputational damages or adverse impact to our business due to security breaches, cyber-attacks, other cybersecurity events or incidents or disclosure of confidential information or personal data;
•compliance or failure to comply with obligations arising under new or existing laws, regulations, and customer contracts relating to the privacy, security and handling of personal data;
•our inability to comply with existing and new laws and regulations, including economic sanctions, export controls, AI regulations, and social and environmental responsibility regulations, policies, and provisions, as well as customer and investor demands;
•failure to maintain our credit rating, manage our indebtedness, and raise additional capital for future needs, which could adversely affect our liquidity, capital position, borrowing costs, and access to capital markets;
•the risks associated with our international operations, including fluctuations in exchange rates, geopolitical conflicts such as the ongoing conflict between Russia and Ukraine and hostilities in the Middle East, and disruptions to our operations;
31
•the risks associated with prolonged periods of inflation or macroeconomic conditions, including reduced customer spending, the uncertainty related to our cost-takeout efforts, and our ability to close new deals in the event of an economic slowdown;
•our inability to compete effectively, maintain and grow our customer relationships over time, collect receivables from customers experiencing financial difficulties, or comply with customer contracts or government contracting regulations or requirements;
•our inability to succeed in our strategic transactions, including acquisitions, divestitures, and strategic partnerships;
•disruption of our supply chain or increases in procurement costs, including as a result of ongoing trade tensions, tariff charges, supplier non-performance, or armed hostilities;
•the risks associated with climate change and natural disasters;
•increased scrutiny of, and evolving expectations for, sustainability and environmental, social and governance ("ESG") initiatives;
•our inadvertent infringement of third-party intellectual property rights or infringement of our intellectual property rights by third parties;
•our inability to procure third-party licenses required for the operation of our products and service offerings;
•our inability to achieve the expected benefits of our restructuring plans, including risks associated with workforce reductions and increased reliance on automation and AI;
•our inability to maintain effective disclosure controls and internal control over financial reporting;
•potential losses due to asset impairment charges, including but not limited to intangibles and deferred tax assets;
•our inability to pay dividends or repurchase shares of our common stock;
•pending investigations, claims and disputes and any adverse impact on our profitability and liquidity;
•changes in tax rates, tax laws, and the timing and outcome of tax examinations;
•volatility of the price of our securities, which is subject to market and other conditions;
•risks following the merger of Computer Sciences Corporation (“CSC”) and Enterprise Services business of Hewlett Packard Enterprise Company’s (“HPE”) businesses, including anticipated tax treatment, unforeseen liabilities, and future capital expenditures;
•risks following the spin-off of our former U.S. Public Sector business (the “USPS”) and its related mergers with Vencore Holding Corp. and KeyPoint Government Solutions in June 2018 to form Perspecta Inc. (including its successors and permitted assigns, “Perspecta”) (collectively the “USPS Separation and Mergers”); and
•the other factors described in Part I, Item 1A “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended March 31, 2026 and subsequent SEC filings, including Part II, Item 1A “Risk Factors” of this Quarterly Report on Form 10-Q.
32
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Introduction
The purpose of the Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is to present information that management believes is relevant to an assessment and understanding of our results of operations and cash flows for the second quarter and first six months of fiscal 2027 and our financial condition as of September 30, 2026. The MD&A is provided as a supplement to, and should be read in conjunction with, our financial statements and accompanying notes.
The MD&A is organized in the following sections:
•Background
•Results of Operations
•Liquidity and Capital Resources
•Critical Accounting Estimates
The following discussion includes a comparison of our results of operations and liquidity and capital resources for the second quarters and first six months of fiscal 2027 and fiscal 2026. References are made throughout to the numbered Notes to the Condensed Consolidated Financial Statements (“Notes”) in this Quarterly Report on Form 10-Q.
Background
DXC is a leading enterprise technology and innovation partner delivering software, services, and solutions to global enterprises and public sector organizations — helping them harness AI to drive outcomes at a time of exponential change with speed. With deep expertise in Managed Infrastructure Services, Application Modernization, and Industry-Specific Software Solutions, DXC modernizes, secures, and operates some of the world’s most complex technology estates.
We generate revenue by offering a broad range of information technology services and solutions to customers primarily in North America, Europe, Asia, and Australia. Our financial results are reported through three reportable segments that reflect the Company’s operational structure and how we deliver end-to-end IT solutions: Consulting & Engineering Services ("CES"), Global Infrastructure Services ("GIS"), and Insurance Software & Services ("Insurance").
Key Metrics
Key revenue, profitability and cash flow metrics for the second quarter of fiscal 2027 compared to the second quarter of fiscal 2026 as well as year to date cash flow comparisons are included below. Organic revenue, adjusted earnings before income taxes, and adjusted diluted earnings per share are non-GAAP financial measures. For more information see “Non-GAAP Financial Measures.”
•Revenues of $3.0 billion, down 4.0% on an organic basis;
•EBIT was $66 million, down 52.2% with a corresponding margin of 2.2%. Adjusted EBIT was $187 million, down 26.4% with a corresponding margin of 6.2%;
•Diluted earnings per share of $0.15, compared to $0.20 in the same period a year ago; adjusted diluted earnings per share of $0.67, compared to $0.84 in the same period a year ago;
•Year-to-date fiscal 2027 cash generated from operations was $635 million, less capital expenditures of $230 million, resulted in free cash flow of $405 million, compared to free cash flow of $337 million in the prior-year period. Free cash flow in fiscal 2027 includes cash proceeds of $214 million related to the litigation judgment obtained against TCS and also a cash outflow of $122 million related to tax deposits made with the IRS, as discussed in Note 12 - “Income Taxes”;
•Book-to-bill ratio (contract awards divided by quarterly revenue) of 0.80x, compared to 0.85x in the prior-year period.
33
Segment Highlights - Second Quarter Fiscal 2027
Consulting & Engineering Services
• Revenue was $1,213 million, down 3.3% year-over-year on an organic basis.
• Segment profit was $125 million, down 13.8% year-over-year, with a corresponding margin of 10.3%.
• Book-to-bill ratio of 0.79x, compared to 0.92x during the second quarter of fiscal 2026.
Global Infrastructure Services
• Revenue was $1,427 million, down 10.0% year-over-year on an organic basis.
• Segment profit was $66 million, down 45.9% year-over-year, with a corresponding margin of 4.6%.
• Book-to-bill ratio of 0.80x, compared to 0.82x during the second quarter of fiscal 2026.
Insurance Services
• Revenue was $394 million, up 23.1% year-over-year on an organic basis. Organic revenue growth includes a favorable contract modification entered into during the second quarter of fiscal 2027.
• Segment profit was $45 million, up 60.7% year-over-year, with a corresponding margin of 11.4%.
• Book-to-bill ratio of 0.79x, compared to 0.68x during the second quarter of fiscal 2026.
Segment Highlights - First Six Months Fiscal 2027
Consulting & Engineering Services
• Revenue was $2,444 million, down 3.1% year-over-year on an organic basis.
• Segment profit was $225 million, down 10.0% year-over-year, with a corresponding margin of 9.2%.
Global Infrastructure Services
• Revenue was $2,876 million, down 10.6% year-over-year on an organic basis.
• Segment profit was $104 million, down 52.5% year-over-year, with a corresponding margin of 3.6%.
Insurance Services
• Revenue was $713 million, up 12.4% year-over-year on an organic basis.
• Segment profit was $79 million, up 29.5% year-over-year, with a corresponding margin of 11.1%.
34
Revenues
Our revenues by geography and operating segment are provided below:
| Three Months Ended | Percentage Change | Percentage of Revenue for the Three Months Ended | ||||||||||||||||||||||||||||||||||||
| (in millions) | September 30, 2026 | September 30, 2025 | U.S. Dollars | Constant Currency(1) | September 30, 2026 | September 30, 2025 | ||||||||||||||||||||||||||||||||
| Geographic Market | ||||||||||||||||||||||||||||||||||||||
| United States | $ | 747 | $ | 821 | (9.0) | % | (9.0) | % | 24.6 | % | 26.0 | % | ||||||||||||||||||||||||||
United Kingdom | 465 | 464 | 0.2 | % | 0.4 | % | 15.3 | % | 14.7 | % | ||||||||||||||||||||||||||||
| Other Europe | 995 | 1,040 | (4.3) | % | (3.2) | % | 32.8 | % | 32.9 | % | ||||||||||||||||||||||||||||
| Australia | 283 | 275 | 2.9 | % | (4.4) | % | 9.3 | % | 8.7 | % | ||||||||||||||||||||||||||||
| Other International | 544 | 561 | (3.0) | % | (1.8) | % | 17.9 | % | 17.7 | % | ||||||||||||||||||||||||||||
| Total Revenues | $ | 3,034 | $ | 3,161 | (4.0) | % | (4.0) | % | 100.0 | % | 100.0 | % | ||||||||||||||||||||||||||
Operating Segments | ||||||||||||||||||||||||||||||||||||||
| CES | $ | 1,213 | $ | 1,255 | (3.3) | % | (3.3) | % | 40.0 | % | 39.7 | % | ||||||||||||||||||||||||||
| GIS | 1,427 | 1,586 | (10.0) | % | (10.0) | % | 47.0 | % | 50.2 | % | ||||||||||||||||||||||||||||
| Insurance | 394 | 320 | 23.1 | % | 23.1 | % | 13.0 | % | 10.1 | % | ||||||||||||||||||||||||||||
| Total Revenues | $ | 3,034 | $ | 3,161 | (4.0) | % | (4.0) | % | 100.0 | % | 100.0 | % | ||||||||||||||||||||||||||
| Six Months Ended | Percentage Change | Percentage of Revenue for the Six Months Ended | ||||||||||||||||||||||||||||||||||||
| (in millions) | September 30, 2026 | September 30, 2025 | U.S. Dollars | Constant Currency(1) | September 30, 2026 | September 30, 2025 | ||||||||||||||||||||||||||||||||
| Geographic Market | ||||||||||||||||||||||||||||||||||||||
| United States | $ | 1,489 | $ | 1,649 | (9.7) | % | (9.7) | % | 24.7 | % | 26.1 | % | ||||||||||||||||||||||||||
United Kingdom | 866 | 944 | (8.3) | % | (8.3) | % | 14.4 | % | 14.9 | % | ||||||||||||||||||||||||||||
| Other Europe | 2,034 | 2,078 | (2.1) | % | (2.6) | % | 33.7 | % | 32.9 | % | ||||||||||||||||||||||||||||
| Australia | 571 | 534 | 6.9 | % | (2.1) | % | 9.5 | % | 8.4 | % | ||||||||||||||||||||||||||||
| Other International | 1,073 | 1,115 | (3.8) | % | (3.0) | % | 17.8 | % | 17.6 | % | ||||||||||||||||||||||||||||
| Total Revenues | $ | 6,033 | $ | 6,320 | (4.5) | % | (5.3) | % | 100.0 | % | 100.0 | % | ||||||||||||||||||||||||||
Operating Segments | ||||||||||||||||||||||||||||||||||||||
| CES | $ | 2,444 | $ | 2,501 | (2.3) | % | (3.1) | % | 40.5 | % | 39.6 | % | ||||||||||||||||||||||||||
| GIS | 2,876 | 3,186 | (9.7) | % | (10.6) | % | 47.7 | % | 50.4 | % | ||||||||||||||||||||||||||||
| Insurance | 713 | 633 | 12.6 | % | 12.4 | % | 11.8 | % | 10.0 | % | ||||||||||||||||||||||||||||
| Total Revenues | $ | 6,033 | $ | 6,320 | (4.5) | % | (5.3) | % | 100.0 | % | 100.0 | % | ||||||||||||||||||||||||||
_____________
(1)Constant currency revenues are a non-GAAP measure calculated by translating current period activity into U.S. dollars using the comparable prior period’s currency conversion rates. This information is consistent with how management views our revenues and evaluates our operating performance and trends. For more information, see "Non-GAAP Financial Measures."
35
For the second quarter of fiscal 2027, our total revenue was $3.0 billion, a decrease of $127 million or 4.0% on an organic basis, compared to the same period a year ago. Organic revenue growth is a non-GAAP measure. For more information, see "Non-GAAP Financial Measures."
For the first six months of fiscal 2027, our total revenue was $6.0 billion, a decrease of $287 million or 4.5%, as compared to the same period a year ago. The decrease against the comparative period includes a 5.3% decline in organic revenue partially offset by a 0.8% favorable foreign currency exchange rate impact.
For the discussion of risks associated with our foreign operations, see Part 1, Item 1A “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended March 31, 2026.
Costs and Expenses
Our total costs and expenses are provided below:
| Three Months Ended September 30, | Change | Six Months Ended September 30, | Change | |||||||||||||||||||||||||||||||||||||||||||||||
| (in millions) | 2026 | 2025 | Dollar | Percent | 2026 | 2025 | Dollar | Percent | ||||||||||||||||||||||||||||||||||||||||||
| Costs of services | $ | 2,374 | $ | 2,383 | $ | (9) | (0.4) | % | $ | 4,762 | $ | 4,771 | $ | (9) | (0.2) | % | ||||||||||||||||||||||||||||||||||
| Selling, general and administrative | 319 | 366 | (47) | (12.8) | % | 647 | 760 | (113) | (14.9) | % | ||||||||||||||||||||||||||||||||||||||||
| Depreciation and amortization | 286 | 295 | (9) | (3.1) | % | 553 | 599 | (46) | (7.7) | % | ||||||||||||||||||||||||||||||||||||||||
| Restructuring costs | 23 | 35 | (12) | (34.3) | % | 49 | 72 | (23) | (31.9) | % | ||||||||||||||||||||||||||||||||||||||||
| Interest expense | 57 | 53 | 4 | 7.5 | % | 112 | 107 | 5 | 4.7 | % | ||||||||||||||||||||||||||||||||||||||||
| Interest income | (45) | (46) | 1 | (2.2) | % | (134) | (92) | (42) | 45.7 | % | ||||||||||||||||||||||||||||||||||||||||
| Other income, net | (34) | (56) | 22 | (39.3) | % | (251) | (95) | (156) | 164.2 | % | ||||||||||||||||||||||||||||||||||||||||
| Total costs and expenses | $ | 2,980 | $ | 3,030 | $ | (50) | (1.7) | % | $ | 5,738 | $ | 6,122 | $ | (384) | (6.3) | % | ||||||||||||||||||||||||||||||||||
Costs of Services
Costs of services, excluding depreciation and amortization and restructuring costs ("COS"), consist of expenses directly associated with revenue-generating activities. These expenses primarily include payroll and related employee benefit costs, subcontractor costs and other contract-related expenses, as well as technology, facilities, and other supporting infrastructure costs.
COS was $2.4 billion for the second quarter of fiscal 2027, a decrease of $9 million (-0.4%) compared to the prior-year period. COS was $4.8 billion for the first six months of fiscal 2027, a decrease of $9 million (-0.2%) compared to the prior-year period. The decline in both periods primarily reflects lower revenue levels and reduced professional services and contractor-related expenses resulting from our cost optimization initiatives, partially offset by a one-time impairment of transition and transformation costs related to a customer contract modification in the second quarter of fiscal 2027.
Gross margin was 21.8% and 21.1% for the second quarter and first six months of fiscal 2027, respectively, a decrease of 280 basis points and 340 basis points against the comparative periods.
36
Selling, General and Administrative
Selling, general and administrative expense, excluding depreciation and amortization and restructuring costs ("SG&A"), consist of the costs associated with personnel in non-client facing positions. These expenses primarily include payroll and related employee benefit costs, business development efforts, marketing and advertising activities, and other expenses such as information systems and office space.
SG&A was $319 million for the second quarter of fiscal 2027, a decrease of $47 million (-12.8%) compared to the prior-year period. SG&A was $647 million for the first six months of fiscal 2027, a decrease of $113 million (-14.9%) compared to the prior-year period. The decline in both periods was primarily driven by lower payroll and related employee benefit costs, as well as reduced professional services and contractor related expenses.
SG&A as a percentage of revenue was 10.5% and 10.7% for the second quarter and first six months of fiscal 2027, respectively, an improvement of 110 basis points and 130 basis points against the comparative periods.
Depreciation and Amortization
Depreciation and amortization was $286 million for the second quarter of fiscal 2027, a decrease of $9 million (-3.1%) compared to the prior-year period. Depreciation expense decreased by $10 million due to lower average net property and equipment balances. Amortization expense increased by $1 million, as a one-time acceleration of software amortization related to a customer contract modification more than offset lower amortization associated with software assets and transition and transformation contract costs.
Depreciation and amortization was $553 million for the first six months of fiscal 2027, a decrease of $46 million (-7.7%) compared to the prior-year period. Depreciation expense decreased by $22 million due to lower average net property and equipment balances. Amortization expense decreased by $24 million due to lower software amortization and transition and transformation contract cost balances, partially offset by a one-time acceleration of software amortization during the second quarter of fiscal 2027.
Restructuring Costs
During fiscal 2027, management approved global cost savings initiatives designed to better align our workforce, facility and data center requirements. During the second quarter and first six months of fiscal 2027, total restructuring costs recorded, net of reversals, were $23 million and $49 million, respectively, a decrease of $12 million (-34.3%) and $23 million (-31.9%), respectively, as compared to the prior-year periods.
See Note 10 – “Restructuring Costs” for additional information about our restructuring actions.
Interest Income and Interest Expense
Net interest expense (interest expense less interest income) was $12 million for the second quarter of fiscal 2027, an increase of $5 million, as compared to the prior-year period. The increase was primarily driven by lower net income from cash deposits, notional pooling arrangements, and leases.
Net interest income was $22 million for the first six months of fiscal 2027 an increase of $37 million, as compared to the prior-year period. Included in this amount is $46 million of interest income from the TCS litigation judgment, partially offset by lower net income from cash deposits, notional pooling arrangements, and leases.
37
Other Income, Net
The components of Other income, net for the second quarters and first six months of fiscal 2027 and 2026 were as follows:
| Three Months Ended September 30, | Six Months Ended September 30, | |||||||||||||||||||||||||||||||||||||
| (in millions) | 2026 | 2025 | Dollar Change | 2026 | 2025 | Dollar Change | ||||||||||||||||||||||||||||||||
| Non-service cost components of net periodic pension income | $ | (46) | $ | (43) | $ | (3) | $ | (91) | $ | (86) | $ | (5) | ||||||||||||||||||||||||||
| Foreign currency loss (gain) | 1 | (2) | 3 | — | (7) | 7 | ||||||||||||||||||||||||||||||||
| Gain on litigation | — | — | — | (168) | — | (168) | ||||||||||||||||||||||||||||||||
| Loss (gain) on real estate and facility sales | 10 | (7) | 17 | 10 | (7) | 17 | ||||||||||||||||||||||||||||||||
Other (gain) loss | 1 | (4) | 5 | (2) | 5 | (7) | ||||||||||||||||||||||||||||||||
| Total | $ | (34) | $ | (56) | $ | 22 | $ | (251) | $ | (95) | $ | (156) | ||||||||||||||||||||||||||
Other income, net was $34 million in the second quarter of fiscal 2027, a decrease of $22 million, as compared to the prior-year period. The decrease was primarily due to a $17 million unfavorable change in gains and losses on real estate and facility sales.
Other income, net was $251 million for the first six months of fiscal 2027, an increase of $156 million, as compared to the prior-year period. The increase was primarily due to the $168 million litigation judgment against TCS recognized in the first quarter, partially offset by a $17 million unfavorable change in gains and losses on real estate and facility sales.
Taxes
Our effective tax rate (“ETR”) was 75.9% and 69.5% for the three months ended September 30, 2026, and September 30, 2025, respectively, and 52.9% and 70.7% for the six months ended September 30, 2026, and September 30, 2025, respectively. For the three months ended September 30, 2026, the primary drivers of the ETR were the global mix of income, and U.S. tax on foreign income. For the six months ended September 30, 2026, the primary drivers of the ETR were the global mix of income, U.S. tax on foreign income, and a decrease in a deferred tax asset for stock based compensation. For the three months ended September 30, 2025, the primary drivers of the ETR were the global mix of income, U.S. tax on foreign income, and the tax benefit of a worthless stock deduction under section 165(g) of the Internal Revenue Code related to the Company's investment in a wholly owned subsidiary. For the six months ended September 30, 2025, the primary drivers of the ETR were the global mix of income, U.S. tax on foreign income, the tax benefit of a worthless stock deduction under section 165(g) of the Internal Revenue Code related to the Company’s investment in a wholly owned subsidiary, and a decrease in a deferred tax asset for stock based compensation.
Net loss attributable to non-controlling interest
The net loss attributable to non-controlling interest, net of tax, was $11 million and $7 million for the second quarter and first six months of fiscal 2027, respectively, a change of $15 million and $13 million as compared to both periods of the prior fiscal year. These increases were primarily attributable to a one-time impairment of transition and transformation costs related to a customer contract modification within a joint venture.
38
Earnings Per Share
Diluted EPS for the second quarter and first six months of fiscal 2027 was $0.15 and $0.89, respectively, a decrease of $0.05 and an increase of $0.60 compared with the prior-year periods.
Diluted EPS for the second quarter of fiscal 2027 includes $0.10 per share of restructuring costs, $0.01 per share of transaction, separation and integration-related costs, $0.36 per share of amortization of acquired intangible assets, $0.04 per share of losses on real estate, facility sales, and dispositions, and $0.01 per share of tax adjustments.
Diluted EPS for the first six months of fiscal 2027 includes $0.18 per share of restructuring costs, $0.01 per share of transaction, separation and integration-related costs, $0.64 per share of amortization of acquired intangible assets, $(0.70) per share of gain on litigation award, $0.03 per share of losses on real estate, facility sales, and dispositions, and $0.01 per share of tax adjustments.
39
Non-GAAP Financial Measures
We present non-GAAP financial measures of performance which are derived from the statements of operations of DXC. These non-GAAP financial measures include earnings before interest and taxes (“EBIT”), adjusted EBIT, non-GAAP income before income taxes, non-GAAP net income, non-GAAP net income attributable to DXC common stockholders, non-GAAP EPS, organic revenue growth, constant currency revenues, and free cash flow.
We believe EBIT, adjusted EBIT, non-GAAP income before income taxes, non-GAAP net income, non-GAAP net income attributable to DXC common stockholders, and non-GAAP EPS provide investors with useful supplemental information about our operating performance after excluding certain categories of expenses as well as gains and losses on certain dispositions and certain tax adjustments.
We believe constant currency revenues provides investors with useful supplemental information about our revenues after excluding the effect of currency exchange rate fluctuations for currencies other than U.S. dollars in the periods presented. See below for a description of the methodology we use to present constant currency revenues.
One category of expenses excluded from adjusted EBIT, non-GAAP income before income tax, non-GAAP net income, non-GAAP net income attributable to DXC common stockholders, and non-GAAP EPS, incremental amortization of intangible assets acquired through business combinations, if included, may result in a significant difference in period over period amortization expense on a GAAP basis. We exclude amortization of certain acquired intangible assets as these non-cash amounts are inconsistent in amount and frequency and are significantly impacted by the timing and/or size of acquisitions. Although DXC management excludes amortization of acquired intangible assets, primarily customer-related intangible assets, from its non-GAAP expenses, we believe that it is important for investors to understand that such intangible assets were recorded as part of purchase accounting and support revenue generation. Any future transactions may result in a change to the acquired intangible asset balances and associated amortization expense.
Another category of expenses excluded from adjusted EBIT, non-GAAP income before income tax, non-GAAP net income, non-GAAP net income attributable to DXC common stockholders, and non-GAAP EPS is impairment losses, which, if included, may result in a significant difference in period-over-period expense on a GAAP basis. We exclude impairment losses as these non-cash amounts reflect generally an acceleration of what would be multiple periods of expense and are not expected to occur frequently. Further, assets such as goodwill may be significantly impacted by market conditions outside of management’s control.
Selected references are made to revenue growth on an “organic basis” so that certain financial results can be viewed without the impact of fluctuations in foreign currency rates and without the impacts of acquisitions and divestitures, thereby providing comparisons of operating performance from period to period of the business that we have owned during both periods presented. Organic revenue growth is calculated by dividing the year-over-year change in GAAP revenues attributed to organic growth by the GAAP revenues reported in the prior comparable period. Organic revenue is calculated as constant currency revenue excluding the impact of mergers, acquisitions or similar transactions until the one-year anniversary of the transaction and excluding revenues of divestitures during the reporting period. This approach is used for all results where the functional currency is not the U.S. dollar. We believe organic revenue growth provides investors with useful supplemental information about our revenues after excluding the effect of currency exchange rate fluctuations for currencies other than U.S. dollars and the effects of acquisitions and divestitures in both periods presented.
Free cash flow represents cash flow from operations, less capital expenditures. Free cash flow is utilized by our management, investors, and analysts to evaluate cash available to pay debt, repurchase shares, and provide further investment in the business.
40
There are limitations to the use of the non-GAAP financial measures presented in this report. One of the limitations is that they do not reflect complete financial results. We compensate for this limitation by providing a reconciliation between our non-GAAP financial measures and the respective most directly comparable financial measure calculated and presented in accordance with GAAP. Additionally, other companies, including companies in our industry, may calculate non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes between companies. Selected references are made on a “constant currency basis” so that certain financial results can be viewed without the impact of fluctuations in foreign currency rates, thereby providing comparisons of operating performance from period to period. Financial results on a “constant currency basis” are non-GAAP measures calculated by translating current period activity into U.S. Dollars using the comparable prior period’s currency conversion rates. This approach is used for all results where the functional currency is not the U.S. Dollar. Please see “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Results of Operations—Revenues.”
Certain non-GAAP financial measures and the respective most directly comparable financial measures calculated and presented in accordance with GAAP include:
| Three Months Ended September 30, | Change | Six Months Ended September 30, | Change | |||||||||||||||||||||||||||||||||||||||||||||||
| (in millions) | 2026 | 2025 | Dollar | Percent | 2026 | 2025 | Dollar | Percent | ||||||||||||||||||||||||||||||||||||||||||
Income before income taxes | $ | 54 | $ | 131 | $ | (77) | (58.8) | % | $ | 295 | $ | 198 | $ | 97 | 49.0 | % | ||||||||||||||||||||||||||||||||||
| Non-GAAP income before income taxes | $ | 175 | $ | 247 | $ | (72) | (29.1) | % | $ | 313 | $ | 455 | $ | (142) | (31.2) | % | ||||||||||||||||||||||||||||||||||
Net income | $ | 13 | $ | 40 | $ | (27) | (67.5) | % | $ | 139 | $ | 58 | $ | 81 | 139.7 | % | ||||||||||||||||||||||||||||||||||
| Adjusted EBIT | $ | 187 | $ | 254 | $ | (67) | (26.4) | % | $ | 337 | $ | 470 | $ | (133) | (28.3) | % | ||||||||||||||||||||||||||||||||||
Reconciliation of Non-GAAP Financial Measures
Our non-GAAP adjustments include:
•Restructuring costs – includes costs, net of reversals, related to workforce and real estate optimization and other similar charges.
•Transaction, separation and integration-related (“TSI”) costs – includes third party costs related to integration, separation, planning, financing and advisory fees and other similar charges associated with mergers, acquisitions, strategic investments, joint ventures, and dispositions and other similar transactions incurred within one year of such transactions closing, except for costs associated with related disputes, which may arise more than one year after closing.
•Amortization of acquired intangible assets – includes amortization of intangible assets acquired through business combinations.
•Merger-related indemnification – represents the Company’s estimate of potential net liability for tax related indemnifications.
•Gain on litigation award – reflects a gain related to the TCS litigation judgment.
•Gains and losses on real estate and facility sales – gains and losses related to dispositions of real property.
•Gains and losses on dispositions – gains and losses related to dispositions of businesses, strategic assets and interests in less than wholly-owned entities.
•Impairment losses – non-cash charges associated with the permanent reduction in the value of the Company’s assets (e.g., impairment of goodwill and other long-term assets including fixed assets and impairments to deferred tax assets for discrete changes in valuation allowances). Future discrete reversals of valuation allowances are likewise excluded.
•Tax adjustments – discrete tax adjustments to impair or recognize certain deferred tax assets, adjustments for changes in tax legislation and the impact of merger and divestitures. Income tax expense of all other (non-discrete) non-GAAP adjustments is based on the difference in the GAAP annual effective tax rate (AETR) and overall non-GAAP provision (consistent with the GAAP methodology).
41
A reconciliation of reported results to non-GAAP results is as follows:
| Three Months Ended September 30, 2026 | ||||||||||||||||||||||||||||||||||||||||||||
| (in millions, except per-share amounts) | As Reported | Restructuring Costs | Transaction, Separation and Integration-Related Costs | Amortization of Acquired Intangible Assets | (Gains) and Losses on Real Estate, Facility Sales and Dispositions | Tax Adjustment | Non-GAAP Results | |||||||||||||||||||||||||||||||||||||
| Income before income taxes | $ | 54 | $ | 23 | $ | 3 | $ | 86 | $ | 9 | $ | — | $ | 175 | ||||||||||||||||||||||||||||||
| Income tax expense | 41 | 7 | 1 | 28 | 3 | (2) | 78 | |||||||||||||||||||||||||||||||||||||
| Net income | 13 | 16 | 2 | 58 | 6 | 2 | 97 | |||||||||||||||||||||||||||||||||||||
| Less: net loss attributable to non-controlling interest, net of tax | (11) | — | — | — | — | — | (11) | |||||||||||||||||||||||||||||||||||||
| Net income attributable to DXC common stockholders | $ | 24 | $ | 16 | $ | 2 | $ | 58 | $ | 6 | $ | 2 | $ | 108 | ||||||||||||||||||||||||||||||
| Effective Tax Rate | 75.9 | % | 44.6 | % | ||||||||||||||||||||||||||||||||||||||||
| Basic EPS from continuing operations | $ | 0.15 | $ | 0.10 | $ | 0.01 | $ | 0.37 | $ | 0.04 | $ | 0.01 | $ | 0.68 | ||||||||||||||||||||||||||||||
| Diluted EPS from continuing operations | $ | 0.15 | $ | 0.10 | $ | 0.01 | $ | 0.36 | $ | 0.04 | $ | 0.01 | $ | 0.67 | ||||||||||||||||||||||||||||||
| Weighted average common shares outstanding for: | ||||||||||||||||||||||||||||||||||||||||||||
| Basic EPS | 158.16 | 158.16 | 158.16 | 158.16 | 158.16 | 158.16 | 158.16 | |||||||||||||||||||||||||||||||||||||
| Diluted EPS | 161.99 | 161.99 | 161.99 | 161.99 | 161.99 | 161.99 | 161.99 | |||||||||||||||||||||||||||||||||||||
| Six Months Ended September 30, 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| (in millions, except per-share amounts) | As Reported | Restructuring Costs | Transaction, Separation and Integration-Related Costs | Amortization of Acquired Intangible Assets | Gain on Litigation Award | (Gains) and Losses on Real Estate, Facility Sales and Dispositions | Tax Adjustment | Non-GAAP Results | ||||||||||||||||||||||||||||||||||||||||||
| Income before income taxes | $ | 295 | $ | 49 | $ | 3 | $ | 173 | $ | (214) | $ | 7 | $ | — | $ | 313 | ||||||||||||||||||||||||||||||||||
| Income tax expense | 156 | 19 | 1 | 68 | (99) | 2 | (2) | 145 | ||||||||||||||||||||||||||||||||||||||||||
| Net income | 139 | 30 | 2 | 105 | (115) | 5 | 2 | 168 | ||||||||||||||||||||||||||||||||||||||||||
| Less: net loss attributable to non-controlling interest, net of tax | (7) | — | — | — | — | — | — | (7) | ||||||||||||||||||||||||||||||||||||||||||
| Net income attributable to DXC common stockholders | $ | 146 | $ | 30 | $ | 2 | $ | 105 | $ | (115) | $ | 5 | $ | 2 | $ | 175 | ||||||||||||||||||||||||||||||||||
| Effective Tax Rate | 52.9 | % | 46.3 | % | ||||||||||||||||||||||||||||||||||||||||||||||
| Basic EPS from continuing operations | $ | 0.91 | $ | 0.19 | $ | 0.01 | $ | 0.65 | $ | (0.72) | $ | 0.03 | $ | 0.01 | $ | 1.09 | ||||||||||||||||||||||||||||||||||
| Diluted EPS from continuing operations | $ | 0.89 | $ | 0.18 | $ | 0.01 | $ | 0.64 | $ | (0.70) | $ | 0.03 | $ | 0.01 | $ | 1.06 | ||||||||||||||||||||||||||||||||||
| Weighted average common shares outstanding for: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Basic EPS | 160.50 | 160.50 | 160.50 | 160.50 | 160.50 | 160.50 | 160.50 | 160.50 | ||||||||||||||||||||||||||||||||||||||||||
| Diluted EPS | 164.39 | 164.39 | 164.39 | 164.39 | 164.39 | 164.39 | 164.39 | 164.39 | ||||||||||||||||||||||||||||||||||||||||||
42
| Three Months Ended September 30, 2025 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| (in millions, except per-share amounts) | As Reported | Restructuring Costs | Transaction, Separation and Integration-Related Costs | Amortization of Acquired Intangible Assets | Merger Related Indemnification | (Gains) and Losses on Real Estate, Facility Sales and Dispositions | Tax Adjustment | Non-GAAP Results | ||||||||||||||||||||||||||||||||||||||||||
| Income before income taxes | $ | 131 | $ | 35 | $ | 1 | $ | 88 | $ | — | $ | (8) | $ | — | $ | 247 | ||||||||||||||||||||||||||||||||||
| Income tax expense | 91 | 6 | — | 15 | (2) | (1) | (16) | 93 | ||||||||||||||||||||||||||||||||||||||||||
| Net income | 40 | 29 | 1 | 73 | 2 | (7) | 16 | 154 | ||||||||||||||||||||||||||||||||||||||||||
| Less: net income attributable to non-controlling interest, net of tax | 4 | — | — | — | — | — | — | 4 | ||||||||||||||||||||||||||||||||||||||||||
| Net income attributable to DXC common stockholders | $ | 36 | $ | 29 | $ | 1 | $ | 73 | $ | 2 | $ | (7) | $ | 16 | $ | 150 | ||||||||||||||||||||||||||||||||||
| Effective Tax Rate | 69.5 | % | 37.7 | % | ||||||||||||||||||||||||||||||||||||||||||||||
| Basic EPS | $ | 0.20 | $ | 0.16 | $ | 0.01 | $ | 0.41 | $ | 0.01 | $ | (0.04) | $ | 0.09 | $ | 0.85 | ||||||||||||||||||||||||||||||||||
| Diluted EPS | $ | 0.20 | $ | 0.16 | $ | 0.01 | $ | 0.41 | $ | 0.01 | $ | (0.04) | $ | 0.09 | $ | 0.84 | ||||||||||||||||||||||||||||||||||
| Weighted average common shares outstanding for: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Basic EPS | 177.43 | 177.43 | 177.43 | 177.43 | 177.43 | 177.43 | 177.43 | 177.43 | ||||||||||||||||||||||||||||||||||||||||||
| Diluted EPS | 179.15 | 179.15 | 179.15 | 179.15 | 179.15 | 179.15 | 179.15 | 179.15 | ||||||||||||||||||||||||||||||||||||||||||
| Six Months Ended September 30, 2025 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| (in millions, except per-share amounts) | As Reported | Restructuring Costs | Transaction, Separation and Integration-Related Costs | Amortization of Acquired Intangible Assets | Merger Related Indemnification | (Gains) and Losses on Real Estate, Facility Sales and Dispositions | Impairment Losses | Tax Adjustment | Non-GAAP Results | |||||||||||||||||||||||||||||||||||||||||||||||
| Income before income taxes | $ | 198 | $ | 72 | $ | 2 | $ | 175 | $ | 2 | $ | (8) | $ | 14 | $ | — | $ | 455 | ||||||||||||||||||||||||||||||||||||||
| Income tax expense | 140 | 15 | — | 35 | (2) | (1) | 4 | (18) | 173 | |||||||||||||||||||||||||||||||||||||||||||||||
| Net income | 58 | 57 | 2 | 140 | 4 | (7) | 10 | 18 | 282 | |||||||||||||||||||||||||||||||||||||||||||||||
| Less: net income attributable to non-controlling interest, net of tax | 6 | — | — | — | — | — | — | — | 6 | |||||||||||||||||||||||||||||||||||||||||||||||
| Net income attributable to DXC common stockholders | $ | 52 | $ | 57 | $ | 2 | $ | 140 | $ | 4 | $ | (7) | $ | 10 | $ | 18 | $ | 276 | ||||||||||||||||||||||||||||||||||||||
| Effective Tax Rate | 70.7 | % | 38.0 | % | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Basic EPS | $ | 0.29 | $ | 0.32 | $ | 0.01 | $ | 0.78 | $ | 0.02 | $ | (0.04) | $ | 0.06 | $ | 0.10 | $ | 1.54 | ||||||||||||||||||||||||||||||||||||||
| Diluted EPS | $ | 0.29 | $ | 0.31 | $ | 0.01 | $ | 0.77 | $ | 0.02 | $ | (0.04) | $ | 0.06 | $ | 0.10 | $ | 1.52 | ||||||||||||||||||||||||||||||||||||||
| Weighted average common shares outstanding for: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Basic EPS | 179.26 | 179.26 | 179.26 | 179.26 | 179.26 | 179.26 | 179.26 | 179.26 | 179.26 | |||||||||||||||||||||||||||||||||||||||||||||||
| Diluted EPS | 181.76 | 181.76 | 181.76 | 181.76 | 181.76 | 181.76 | 181.76 | 181.76 | 181.76 | |||||||||||||||||||||||||||||||||||||||||||||||
43
Reconciliations of revenue growth to organic revenue growth are as follows:
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||
| (in millions) | September 30, 2026 | September 30, 2025 | September 30, 2026 | September 30, 2025 | ||||||||||||||||||||||
| Total revenue growth | (4.0) | % | (2.5) | % | (4.5) | % | (2.4) | % | ||||||||||||||||||
| Foreign currency | — | % | (1.9) | % | (0.8) | % | (2.0) | % | ||||||||||||||||||
| Acquisitions and Divestitures | — | % | 0.2 | % | — | % | 0.1 | % | ||||||||||||||||||
| Organic revenue growth | (4.0) | % | (4.2) | % | (5.3) | % | (4.3) | % | ||||||||||||||||||
| CES revenue growth | (3.3) | % | (1.9) | % | (2.3) | % | (2.3) | % | ||||||||||||||||||
| Foreign currency | — | % | (1.9) | % | (0.8) | % | (2.0) | % | ||||||||||||||||||
| Acquisitions and Divestitures | — | % | 0.4 | % | — | % | 0.4 | % | ||||||||||||||||||
| CES organic revenue growth | (3.3) | % | (3.4) | % | (3.1) | % | (3.9) | % | ||||||||||||||||||
| GIS revenue growth | (10.0) | % | (4.2) | % | (9.7) | % | (3.9) | % | ||||||||||||||||||
| Foreign currency | — | % | (2.1) | % | (0.9) | % | (2.1) | % | ||||||||||||||||||
| Acquisitions and Divestitures | — | % | — | % | — | % | — | % | ||||||||||||||||||
| GIS organic revenue growth | (10.0) | % | (6.3) | % | (10.6) | % | (6.0) | % | ||||||||||||||||||
| Insurance revenue growth | 23.1 | % | 4.6 | % | 12.6 | % | 5.0 | % | ||||||||||||||||||
| Foreign currency | — | % | (1.0) | % | (0.2) | % | (1.4) | % | ||||||||||||||||||
| Acquisitions and Divestitures | — | % | — | % | — | % | — | % | ||||||||||||||||||
| Insurance organic revenue growth | 23.1 | % | 3.6 | % | 12.4 | % | 3.6 | % | ||||||||||||||||||
Reconciliations of segment profit and adjusted EBIT to net income are as follows:
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||
| (in millions) | September 30, 2026 | September 30, 2025 | September 30, 2026 | September 30, 2025 | ||||||||||||||||||||||
| Total profit for reportable segments | $ | 236 | $ | 295 | $ | 408 | $ | 530 | ||||||||||||||||||
Corporate expenses | (49) | (41) | (71) | (60) | ||||||||||||||||||||||
Adjusted EBIT | 187 | 254 | 337 | 470 | ||||||||||||||||||||||
| Restructuring costs | (23) | (35) | (49) | (72) | ||||||||||||||||||||||
| Transaction, separation and integration-related costs | (3) | (1) | (3) | (2) | ||||||||||||||||||||||
| Amortization of acquired intangible assets | (86) | (88) | (173) | (175) | ||||||||||||||||||||||
| Merger related indemnification | — | — | — | (2) | ||||||||||||||||||||||
| Gain on litigation award | — | — | 168 | — | ||||||||||||||||||||||
| (Losses) gains on real estate, facility sales and dispositions | (9) | 8 | (7) | 8 | ||||||||||||||||||||||
| Impairment losses | — | — | — | (14) | ||||||||||||||||||||||
EBIT | 66 | 138 | 273 | 213 | ||||||||||||||||||||||
| Interest income | 45 | 46 | 134 | 92 | ||||||||||||||||||||||
Interest expense | (57) | (53) | (112) | (107) | ||||||||||||||||||||||
| Income before income taxes | 54 | 131 | 295 | 198 | ||||||||||||||||||||||
| Income tax expense | (41) | (91) | (156) | (140) | ||||||||||||||||||||||
| Net income | $ | 13 | $ | 40 | $ | 139 | $ | 58 | ||||||||||||||||||
44
Liquidity and Capital Resources
Cash and Cash Equivalents and Cash Flows
As of September 30, 2026, our cash and cash equivalents (“cash”) were $1.6 billion, of which $0.8 billion was held outside of the U.S. We maintain various multi-currency, multi-entity, cross-border, physical and notional cash pool arrangements with various counterparties to manage liquidity efficiently that enable participating subsidiaries to draw on the Company’s pooled resources to meet liquidity needs.
A significant portion of the cash held by our foreign subsidiaries is not expected to be impacted by U.S. federal income tax upon repatriation. However, a portion of this cash may still be subject to foreign and U.S. state income tax consequences upon future remittance. Therefore, if additional funds held outside the U.S. are needed for our operations in the U.S., we plan to repatriate these funds not designated as indefinitely reinvested.
We have $0.1 billion in cash held by foreign subsidiaries used for local operations that is subject to country-specific limitations which may restrict or result in increased costs in the repatriation of these funds. In addition, other practical considerations may limit our use of consolidated cash. This includes cash of $0.2 billion held by majority-owned consolidated subsidiaries where third-parties or public shareholders hold minority interests.
The following table summarizes our cash flow activity:
| Six Months Ended | ||||||||||||||||||||
| (in millions) | September 30, 2026 | September 30, 2025 | Change | |||||||||||||||||
| Net cash provided by (used in): | ||||||||||||||||||||
| Operating activities | $ | 635 | $ | 595 | $ | 40 | ||||||||||||||
| Investing activities | (187) | (222) | 35 | |||||||||||||||||
| Financing activities | (618) | (246) | (372) | |||||||||||||||||
| Effect of exchange rate changes on cash and cash equivalents | 32 | (35) | 67 | |||||||||||||||||
| Net (decrease) increase in cash and cash equivalents | $ | (138) | $ | 92 | $ | (230) | ||||||||||||||
| Cash and cash equivalents at beginning of year | 1,737 | 1,796 | ||||||||||||||||||
| Cash and cash equivalents at the end of period | $ | 1,599 | $ | 1,888 | ||||||||||||||||
Operating cash flow
Net cash provided by operating activities was $635 million and $595 million, respectively, during the first six months of fiscal 2027 and fiscal 2026, reflecting a year-over year increase of $40 million. The increase was primarily due to:
•a $62 million increase in net income, net of adjustments, including $214 million of proceeds related to the TCS litigation judgment; partially offset by
•a $22 million unfavorable change in working capital, including $122 million of deposits made with the IRS, as discussed in Note 12 - “Income Taxes.”
The following table contains certain key working capital metrics:
| Three Months Ended | ||||||||||||||||||||
| September 30, 2026 | September 30, 2025 | |||||||||||||||||||
| Days of sales outstanding in accounts receivable | 68 | 66 | ||||||||||||||||||
| Days of purchases outstanding in accounts payable | (49) | (57) | ||||||||||||||||||
| Cash conversion cycle | 19 | 9 | ||||||||||||||||||
45
Investing cash flow
Net cash used in investing activities was $187 million and $222 million, respectively, during the first six months of fiscal 2027 and fiscal 2026, reflecting a year-over-year change of $35 million. The change was primarily due to:
•a $28 million decrease in capital expenditures primarily from lower levels of software purchased and developed; and
•a $7 million increase in proceeds from sales of assets and other net investing activities.
Financing cash flow
Net cash used in financing activities was $618 million and $246 million, respectively, during the first six months of fiscal 2027 and fiscal 2026, reflecting a year-over-year change of $372 million. The change was primarily due to:
•a $400 million principal payment on long-term debt in the first six months of fiscal 2027; and
•a $6 million increase in cash used for share repurchases and related tax payments on net share settlements; partially offset by
•a $34 million reduction in payments on capital leases and asset financing arrangements, as the Company continues reducing the volume of these financing activities.
Debt Financing
The following table summarizes our total debt:
| As of | ||||||||||||||||||||
| (in millions) | September 30, 2026 | March 31, 2026 | Change | |||||||||||||||||
| Short-term debt and current maturities of long-term debt | $ | 935 | $ | 520 | $ | 415 | ||||||||||||||
| Long-term debt, net of current maturities | 2,124 | 3,032 | (908) | |||||||||||||||||
| Total debt | $ | 3,059 | $ | 3,552 | $ | (493) | ||||||||||||||
The $493 million decrease in total debt during the first six months of fiscal 2027 was primarily attributable to $400 million in principal payments on long-term debt, reduction in finance leases and borrowings for asset financing attributable to payments exceeding additions, and a favorable foreign currency exchange rate of the U.S. dollar against the Euro.
We were in compliance with all financial covenants associated with our borrowings as of September 30, 2026.
Our credit ratings are as follows:
| Rating Agency | Long Term Ratings | Short Term Ratings | Outlook | |||||||||||||||||
| Fitch | BBB- | F3 | Stable | |||||||||||||||||
| Moody’s | Baa3 | P-3 | Stable | |||||||||||||||||
| S&P | BBB- | - | Stable | |||||||||||||||||
For information on the risks of ratings downgrades, see Part I, Item 1A “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended March 31, 2026.
46
Liquidity
We expect our existing cash and cash equivalents, together with cash generated from operations, will be sufficient to meet our normal operating requirements for the next 12 months and beyond. We expect to continue using cash generated by operations as a primary source of liquidity; however, should we require funds greater than that generated from our operations to fund discretionary investment activities, such as business acquisitions, we have the ability to raise capital through debt financing, including the issuance of capital market debt instruments such as commercial paper, and bonds. In addition, we currently utilize, and will further utilize accounts receivables, sales facilities, and our cross-currency cash pool for liquidity needs. However, there is no guarantee that we will be able to obtain debt financing, if required, on terms and conditions acceptable to us, if at all, in the future.
Our exposure to operational liquidity risk is primarily from long-term contracts that require significant investment of cash during the initial phases of the contracts. The recovery of these investments is over the life of the contracts and is dependent upon our performance as well as customer acceptance.
Our total liquidity of $4.6 billion as of September 30, 2026, includes $1.6 billion of cash and cash equivalents and $3.0 billion of available borrowings under our revolving credit facility.
The Company has $3.0 billion of available borrowings under our revolving credit facility through November 1, 2030. On October 27, 2026, the Company extended $2.8 billion of our revolving credit facility for one additional year to November 1, 2031. The Company believes this revised facility continues to provide ample financial flexibility to support our operating and strategic objectives.
Share Repurchases
See Note 13 – “Stockholders’ Equity.”
Dividends
To maintain our financial flexibility, we continue to suspend payment of quarterly dividends for fiscal 2027.
Off-Balance Sheet Arrangements
In the normal course of business, we are a party to arrangements that include guarantees, the receivables securitization facility and certain other financial instruments with off-balance sheet risk, such as letters of credit and surety bonds. We also use performance letters of credit to support various risk management insurance policies. No liabilities related to these arrangements are reflected in our condensed consolidated balance sheets. There have been no material changes to our off-balance-sheet arrangements reported under Part II, Item 7 of our Annual Report on Form 10-K for the fiscal year ended March 31, 2026, other than as disclosed in Note 3 – “Receivables” and Note 18 – “Commitments and Contingencies.”
Cash Commitments
There have been no material changes, outside the ordinary course of business, to our cash commitments since March 31, 2026. For further information see “Cash Commitments” in Part II, Item 7 of our Annual Report on Form 10-K for the fiscal year ended March 31, 2026.
For our minimum purchase cash commitments in connection with our long-term purchase agreements with certain software, hardware, telecommunication, and other service providers, see Note 18 – “Commitments and Contingencies.”
47
Critical Accounting Estimates
The preparation of consolidated financial statements in accordance with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, as well as the disclosure of contingent assets and liabilities. These estimates may change in the future if underlying assumptions or factors change. Accordingly, actual results could differ materially from our estimates under different assumptions, judgments or conditions. We consider the following policies to be critical because of their complexity and the high degree of judgment involved in implementing them: revenue recognition, income taxes, defined benefit plans, valuation of assets and loss accruals for contingencies and litigation. We have discussed the selection of our critical accounting policies and the effect of estimates with the Audit Committee of our Board of Directors. During the three months ended September 30, 2026, there were no changes to our critical accounting policies and estimates from those described in our Annual Report on Form 10-K for the fiscal year ended March 31, 2026 except as mentioned in Note 1 – “Summary of Significant Accounting Policies.”
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
For quantitative and qualitative disclosures about market risk affecting DXC, see “Quantitative and Qualitative Disclosures About Market Risk” in Part II, Item 7A of our Annual Report on Form 10-K for the fiscal year ended March 31, 2026. Our exposure to market risk has not changed materially since March 31, 2026.
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of September 30, 2026.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting during the three months ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
48
PART II
ITEM 1. LEGAL PROCEEDINGS
See Note 18 – “Commitments and Contingencies” to the financial statements in this Quarterly Report on Form 10-Q under the caption “Contingencies” for information regarding legal proceedings in which we are involved.
ITEM 1A. RISK FACTORS
Our operations and financial results are subject to various risks and uncertainties, which may materially and adversely affect our business, financial condition, and results of operations, and the actual outcome of matters as to which forward-looking statements are made in this Quarterly Report on Form 10-Q. In such case, the trading price for DXC common stock could decline, and you could lose all or part of your investment. Past performance may not be a reliable indicator of future financial performance and historical trends should not be used to anticipate results or trends in future periods. Future performance and historical trends may be adversely affected by the aforementioned risks, and other variables and risks and uncertainties not currently known or that are currently expected to be immaterial may also materially and adversely affect our business, financial condition, and results of operations or the price of our common stock in the future. There have been no material changes in the three months ended September 30, 2026 to the risk factors described in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended March 31, 2026.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Unregistered Sales of Equity Securities
None during the period covered by this report.
Use of Proceeds
Not applicable.
Issuer Purchases of Equity Securities
The following table provides information on a monthly basis for the quarter ended September 30, 2026, with respect to the Company’s purchase of equity securities:
| Period | Total Number of Shares Purchased | Average Price Paid Per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Approximate Dollar Value of Shares that May Yet be Purchased Under the Plans or Programs | ||||||||||||||||||||||
| July 1 to July 31, 2026 | 2,025,999 | $ | 9.87 | 2,025,999 | $ | 251,980,589 | ||||||||||||||||||||
| August 1 to August 31, 2026 | 1,840,450 | $ | 10.87 | 1,840,450 | $ | 231,981,245 | ||||||||||||||||||||
| September 1 to September 30, 2026 | 1,796,305 | $ | 11.13 | 1,796,305 | $ | 211,980,500 | ||||||||||||||||||||
On May 18, 2023, DXC announced that its Board approved an incremental $1.0 billion share repurchase authorization. As of September 30, 2026, approximately $212 million worth of shares remained available for repurchase under the plans or programs. Share repurchases may be made from time to time through various means, including in open market purchases, 10b5-1 plans, privately-negotiated transactions, accelerated stock repurchases, block trades and other transactions, in compliance with Rule 10b-18 under the Exchange Act, as well as, to the extent applicable, other federal and state securities laws and other legal requirements. The timing, volume, and nature of share repurchases pursuant to the share repurchase plan are at the discretion of management and may be suspended or discontinued at any time.
49
On August 16, 2022, the U.S. government enacted the Inflation Reduction Act (the "IRA") into law. The IRA imposes a 1% excise tax on share repurchases completed after December 31, 2022. We reflect the excise tax within equity as part of the repurchase of the common stock.
See Note 13 - "Stockholders’ Equity" to the financial statements in this Quarterly Report on Form 10-Q for more information.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5. OTHER INFORMATION
During the three months ended September 30, 2026, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K.
50
ITEM 6. EXHIBITS
Exhibit Number | Description of Exhibit | ||||
| 10.1+ | |||||
| 10.2^ | |||||
| 10.3*+# | |||||
| 31.1* | |||||
| 31.2* | |||||
| 32.1** | |||||
| 32.2** | |||||
| 101.INS | Interactive Data Files | ||||
| 101.SCH | XBRL Taxonomy Extension Schema | ||||
| 101.CAL | XBRL Taxonomy Extension Calculation | ||||
| 101.LAB | XBRL Taxonomy Extension Labels | ||||
| 101.PRE | XBRL Taxonomy Extension Presentation | ||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | ||||
* Filed herewith
** Furnished herewith
+ Management contract or compensatory plan or arrangement.
# Certain personal information has been redacted from this exhibit pursuant to Item 601(a)(6) of Regulation S-K
^ Certain identified information has been excluded from this exhibit pursuant to Item 601(b)(10)(iv) of Regulation S-K and will be provided to the Securities and Exchange Commission upon request
51
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| DXC TECHNOLOGY COMPANY | |||||||||||
| Dated: | October 29, 2026 | By: | /s/ Christopher A. Voci | ||||||||
| Name: | Christopher A. Voci | ||||||||||
| Title: | Senior Vice President, Corporate Controller and Principal Accounting Officer | ||||||||||
52
Exhibit 10.3 | ||

27 July 2026
Private & Confidential
Paul Taylor
[***]
Dear Paul,
Offer of Employment
On behalf of EntServ UK Limited, a DXC Technology company (Company), I am very pleased to offer you a permanent position as Executive Vice President (EVP), President, Global Offerings & Markets, working five days a week. The terms set out in this letter and the enclosed contract of employment will govern your employment with the Company and supersede any previous discussions or communications about those terms.
Your employment with the Company would be on the terms set out in the enclosed contract of employment. By way of summary, the main elements of your overall remuneration package are:
•an annual base salary of £769,820 gross (paid monthly in arrears on or about the 21st of each month);
•a Company-arranged car and driver for business use in and around London;
•eligibility to participate in the DXC discretionary bonus scheme and long-term incentive plan;
•30 days’ annual holiday, in addition to time off for public holidays;
•participation in the DXC contributory pension scheme and the DXC cash-in-lieu scheme linked to tapered annual allowance;
•annual cash-in-lieu allowance of £25,000 (less tax and deductions);
•participation in DXC’s flexible benefits scheme, using a flexible benefits fund to contribute towards any benefits you select;
•reimbursement of annual tax-preparation in connection with multi-jurisdiction business travel;
•eligibility for business travel under the Company Aircraft Usage Policy.
1
Exhibit 10.3 | ||
In connection with your commencement of employment, you will receive initial equity awards with an aggregate target grant-date value of US$9,000,000. For administrative purposes, this package will be delivered through (i) a US$3,750,000 inducement award and (ii) a US$5,250,000 prorated FY27 long-term incentive award (assuming and conditional upon a commencement date between 2 August 2026 and 31 August 2026). These awards together comprise your agreed initial equity package and will be subject to substantially identical economic terms, including equity mix, vesting schedule, performance conditions and Change in Control treatment. For further details see Appendix 2 of your enclosed contract.
This offer is subject to each of the following conditions:
a)You must provide the Company with three years’ worth of employment references which it considers satisfactory. We will not take up the references until you have accepted the offer.
b)You are required to show the Company a document which confirms that you have the right to work in the UK.
c)You are required to successfully complete a criminal background screening as part of the Global Employment Screening Process, the results of this screening will be reviewed by our panel, and any unspent convictions will be considered for suitability of employment.
d)You are required to maintain security clearance throughout the duration of your employment as a condition of employment where such security clearance is reasonably necessary and cannot be obtained by way of assignment to you.
e)You must confirm in writing that you are not subject to any restrictive covenants or other contractual obligations with any current or former employer that would prevent or restrict you from commencing employment with the Company or performing your duties as EVP, President Global Offerings & Markets. To the extent that any such restrictions exist, you must disclose them in full prior to acceptance of this offer.
Your employment will not commence until these conditions have been satisfied. If they are not satisfied for any reason, the Company may withdraw this offer of employment.
By accepting this offer, you confirm that you are able to accept this job and carry out the work that it would involve without breaching any legal restrictions on your activities, such as restrictions imposed by a current or former employer.
To facilitate you obtaining legal advice on the terms of this employment offer, the Company will reimburse your reasonable legal fees, up to a maximum of £10,000 plus VAT. Please note that this reimbursement may constitute a taxable benefit.
2
Exhibit 10.3 | ||
To accept this offer, please sign and return the enclosed contract of employment. The contract must be executed as a deed, which means your signature must be witnessed by an adult who is not related to you. We would like you to start as soon as possible and, once the conditions above have been satisfied, we will agree a start date with you.
We are delighted to extend this offer and look forward to welcoming you to DXC.
Yours sincerely,
Jennifer Ragone
Chief People Officer
On Behalf of EntServ UK Limited
3
Exhibit 10.3 | ||
Contract of Employment
This deed is dated:
Parties
(1)EntServ UK Limited, a DXC Technology company, incorporated and registered in England and Wales with company number 00053419 whose registered office is at 110 Pinehurst Road, Farnborough Business Park, Farnborough, Hampshire, GU14 7BF, United Kingdom (Company); and
(2)Paul Taylor of [***] (Executive)
Background
This deed is a contract of employment and contains a statement of the applicable terms of the Executive’s employment as required by Section 1 of the Employment Rights Act 1996.
The definitions and rules of interpretation in Appendix 1 apply in this contract of employment.
The headings in this contract of employment are inserted for convenience only and shall not affect its construction.
A reference to a particular law is a reference to it as it is in force for the time being taking account of any amendment, extension, or re-enactment and includes any subordinate legislation for the time being in force made under it.
Agreed Terms
1.COMMENCEMENT OF EMPLOYMENT
The Executive’s employment with the Company will commence on a date to be advised to the Executive by the Company, but no later than 31 August 2026. The Executive’s commencement date shall also be the start of the Executive’s continuous employment and no other period of employment will count toward the Executive’s period of continuous service.
1.1Prior to the commencement of employment with the Company the Executive must successfully complete and obtain the necessary screening and/or security clearance as required by the accompanying offer letter. The Executive must maintain the security clearance appropriate to the Executive’s
4
Exhibit 10.3 | ||
role for the duration of any engagement with a client for which that level of clearance is required. The Executive must promptly notify the Company at any time during the period of employment should any circumstances change which may affect the Company’s screening process, the Executive’s security clearance or should the Executive’s security clearance be revoked for any reason. A failure to keep the Company so notified could result in the termination of the Executive’s employment on the ground of gross misconduct. The Executive’s continued employment with the Company is conditional on the Executive having the necessary security clearances from time to time.
1.2The Executive represents and warrants to the Company that, by entering into this contract of employment or performing any of the Executive’s obligations under it, the Executive will not be in breach of any court order or any express or implied terms of any contract or other obligation binding on the Executive and undertakes to indemnify the Company on a continuous basis against any claims, costs, damages, liabilities or expenses which the Company may incur as a result if the Executive is in breach of any such obligations.
1.3The Executive warrants that the Executive is entitled to work in the UK without any additional approvals and will notify the Company immediately if the Executive ceases to be so entitled at any time during employment with the Company. The Executive’s continued employment with the Company is conditional on the Executive having the right to work in the UK.
1.4The Company may require the Executive to work for any Group Company and reserves the right on reasonable notice to transfer the Executive’s employment to any other Group Company.
2.JOB TITLE
2.1The Executive will be employed as President, Global Offerings and Markets, which is classified as an Executive Vice President (“EVP”) role in the DXC job level architecture. The Executive shall report directly to the Chief Executive Officer of DXC Technology Company.
2.2The Company shall not materially diminish the Executive's title, duties, or responsibilities without the Executive's prior written consent, provided that reasonable adjustments to duties consistent with the Executive's seniority and the evolving needs of the business shall not constitute a material diminution.
2.3The Executive may be required to serve as a director or officer of any Group Company without additional compensation, and to resign from any such position upon the termination of employment.
5
Exhibit 10.3 | ||
3.PLACE OF WORK
3.1The Executive’s normal place of work is [***] or such other place within the UK as the Company may reasonably determine following consultation with the Executive.
3.2The Executive agrees to travel on the Company's or any Group Company's business (both within the United Kingdom or abroad) as may be required for the proper performance of his duties under this contract of employment.
3.3During the term of employment, the Executive shall not be required to work outside the UK for any continuous period of more than one month. Any requirement for the Executive to be required to work outside the UK for any continuous period of more than one month during the term of employment will be in accordance with the relevant policy (such policy does not form part of this contract of employment).
3.4The Company and the Executive acknowledge that relocation to an alternative location may be agreed between the Executive and the Chief Executive Officer from time to time.
3.5For the avoidance of doubt, relocation pursuant to clause 3.4 shall not be imposed unilaterally by the Company, and any change to the Executive's country of employment shall require mutual written agreement and, where applicable, execution of a new or amended contract of employment on terms appropriate to the jurisdiction of relocation.
4.SALARY AND BENEFITS
4.1The Executive’s basic salary is £769,820 per year (paid monthly in arrears on or about the 21st of each month).
4.2In addition, the Executive will receive the equivalent of £12,924.60 per year for the provision of Executive benefits subject to the terms of this clause 4 (“Flex Fund”).
4.3The Executive’s basic salary and Flex Fund will be subject to necessary statutory deductions as required under legislation (including but not limited to any tax, NI, pension contributions or attachment of earnings orders).
4.4The Company shall be entitled to deduct from the Executive’s basic salary, Flex Fund or other payments due to the Executive any money which the Executive may owe to the Company at any time under the terms of this contract of employment or otherwise, including as a result of any
6
Exhibit 10.3 | ||
overpayments by the Company to the Executive. Any outstanding amount, over and above the payment deducted, will be owed by the Executive to the Company as a debt.
4.5The Company currently operates a flexible benefits scheme which enables the Executive to select a benefits package using their basic salary and/or Flex Fund subject to the Company’s agreement. Participation in the scheme is subject to the rules of the scheme and any other applicable scheme rules from time to time in force and subject in each case to the terms of the relevant policy and benefits guidebook (as amended from time to time), the rules of the relevant scheme and the Executive (and, where appropriate, the Executive’s spouse or civil partner and children) being eligible to participate in or benefit from such schemes pursuant to their rules at a cost and on terms which are acceptable to the Company.
4.6The Company currently requires that the Executive uses their Flex Fund and such amounts of the Executive’s salary as is necessary to receive and participate in the death in service scheme (details of which are available in the benefits guidebook).
4.7The Company has also provided the Executive with funding in their Flex Fund to enable the Executive to receive and participate in the private medical scheme (details of which are in the benefits guidebook), however it is not, at this time, mandatory for the Executive to take up the option of the private medical scheme. However, the Company may, at its sole discretion, require the Executive to use their Flex Fund, and such amounts of the Executive’s salary as is necessary, to receive and participate in the private medical scheme.
4.8At the Company’s sole discretion, the Executive may elect to use any remaining Flex Fund for the provision of other benefits under the Company’s flexible benefit schemes or to receive any remaining Flex Fund as cash.
4.9The Company may, at its sole discretion, require the Executive to receive certain other benefits than those listed in clause 4.6, replace or withdraw or amend such schemes (either individual benefit schemes or its overall flexible benefits scheme) or the ability for the Executive to receive the remaining Flex Fund as cash at any time without providing any replacement on one month’s notice to the Executive.
4.10The Executive’s basic salary will be reviewed from time to time but there is no obligation on the Company to award an increase to the Executive’s basic salary.
7
Exhibit 10.3 | ||
4.11Currently, where applicable, provision for the Executive’s benefits will be made through ‘salary sacrifice’ which the Company operates and can be managed annually through the Company’s benefit scheme site.
4.12The cost of benefits under the Company’s flexible benefits scheme may increase or decrease in cost each year and the Executive will be responsible for covering the cost of benefits from their Flex Fund and/or basic salary. The Executive’s Flex Fund may be reviewed from time to time and may be increased at the Company's discretion without affecting the other terms of the Executive’s employment. There is no obligation on the Company to award an increase to the Flex Fund even where the cost of benefits increases.
4.13There will be no review of the Executive’s basic salary and Flex Fund after notice has been given by either party to terminate the Executive’s employment.
4.14The Executive will be paid the Executive’s basic salary and Flex Fund (less any deductions, including flexible benefits purchased) which shall accrue from day to day at a rate of 1/260 and paid monthly in arrears on or about the 21st of each month directly into the Executive’s bank or building society account.
4.15In addition to the salary and benefits package set out above, the Executive will also receive the additional benefits and/or entitlements set out in Appendix 2 of this contract of employment.
5.HOURS OF WORK
5.1The Executive’s normal hours of work are 37.5 hours per week. The Executive will normally be required to work the Company’s business hours between 09.00 and 17.30, Mondays to Fridays, inclusive of a lunch break of one hour. The Executive may be required to work such additional hours as may be necessary for the proper performance of the Executive’s duties without extra remuneration.
5.2The Executive’s normal working hours may be varied by the Company at any time on reasonable notice according to business need, either on a temporary or permanent basis, including if necessary working in the evenings, at weekends or on public holidays.
5.3The Executive shall not be permitted to work overtime if the Executive’s hours would exceed 48 hours per week averaged over a 17-week reference period, unless the Executive has signed the opt-out agreement in Appendix 4.
8
Exhibit 10.3 | ||
6.HOLIDAYS
6.1The Company's holiday year runs between 1st January and 31st December. If employment starts or finishes part way through the holiday year, holiday entitlement during that year shall be calculated on a pro-rata basis.
6.2The Executive is entitled to 30 days' paid holiday during each holiday year or the pro rata equivalent if working part time. In addition, the Executive is entitled to take the local statutory public holidays or a day in lieu where the Company requires the Executive to work on a public holiday.
6.3The Executive may carry forward up to 5 days untaken holiday from one holiday year to the following holiday year, subject to such carried-over holiday being taken by the end of March. In cases of sickness absence, carry-over is limited to four weeks' holiday per year less any leave (including public holidays) taken during the holiday year that has just ended. Any such carried over holiday which is not taken within eighteen months of the end of the relevant holiday year will be lost.
6.4The Company shall not pay the Executive in lieu of untaken holiday except on termination of employment. The amount of such payment in lieu shall be as set out in the Company’s annual leave policy from time to time which is available on the intranet. However, if the Company has dismissed the Executive or would be entitled to dismiss the Executive under clause 10.3 or the Executive has resigned without giving the required notice, such payment in lieu shall be limited to the statutory entitlement under the Working Time Regulations 1998, and any paid holidays (including paid public holidays) taken shall be deemed first to have been taken in satisfaction of that statutory entitlement.
6.5If the Executive has taken more holiday than the Executive’s accrued entitlement at the date the Executive’s employment terminates, the Company shall be entitled to deduct the excess holiday pay from any payments due to the Executive calculated at 1/260th of the Executive’s full-time equivalent basic salary for each excess day.
6.6Any accrued but unused holiday entitlement shall be deemed to be taken during any period of Garden Leave.
7.OTHER PAID LEAVE
7.1You may be eligible to take the following types of paid leave, subject to any statutory eligibility requirements or conditions and the Company's rules applicable to each type of leave in force from time to time:
9
Exhibit 10.3 | ||
(a)statutory paternity leave and you may be eligible to receive Company paternity pay subject to the rules set out in the Company's paternity policy from time to time;
(b)statutory adoption leave and you may be eligible to receive Company adoption pay subject to the rules set out in the Company's adoption policy from time to time;
(c)shared parental leave subject to the rules set out in the Company's shared parental leave policy from time to time;
(d)parental leave subject to the rules set out in the Company's Parental Leave policy from time to time; and
(e)parental bereavement leave subject to the rules set out in the Company's Special Leave policy from time to time.
7.2Further details of such leave are available on the intranet.
7.3The Company may replace, amend or withdraw the Company's policy on any of the above types of leave at any time.
8.TRAVEL AND OTHER EXPENSES
8.1The Company shall reimburse (or procure the reimbursement of) all reasonable expenses wholly, properly and necessarily incurred by the Executive in the course of the Executive’s employment, subject to the Company’s travel and reimbursement policy (as amended from time to time) and receipt of the necessary approvals. The travel and reimbursement policy does not form part of this contract of employment.
8.2Any credit card supplied to the Executive by the Company shall only be used for expenses incurred by the Executive in the course of the Executive’s duties. Failure to comply with this clause 8.2 may result in disciplinary action up to and including the immediate termination of the Executive’s employment.
9.SICKNESS ABSENCE
9.1If the Executive is absent from work due to incapacity, the Executive must notify the Company of the reason for the Executive’s absence as soon as possible but no later than the Executive’s contractual start time on the first day of absence, in accordance with the absence policy (such policy does not form part of this contract of employment).
9.2The Executive shall certify the Executive’s absence in accordance with the Company sickness absence policy which is available on the intranet. The sickness absence policy does not form part of this contract of employment.
10
Exhibit 10.3 | ||
9.3The Executive may be entitled to Statutory Sick Pay (SSP) if the Executive satisfies the relevant statutory requirements. Qualifying days for SSP are Monday to Friday. The rate of SSP is set by the government in April each year.
9.4The Executive shall be entitled to company sick pay calculated as twenty eight (28) weeks' full basic annual salary and twenty four (24) weeks' half basic annual salary in any rolling fifty two (52) week period. When calculating how much company sick pay an Executive has remaining, the 52-week period preceding the first day of each period of absence is used.
9.5If the Executive has exhausted company sick pay, the Executive will not be considered for company sick pay again until the Executive has returned to work without any sickness absence for a continuous period of eighteen (18) weeks.
9.6Any payments of company sick pay made will be inclusive of any SSP. The mechanics of this calculation and when an Executive is entitled to company sick pay is at the Company’s sole discretion and further information is available in the sickness absence policy.
9.7Pension contributions will continue as normal during any period that the Executive is paid company sick pay at full basic pay, if any. If the Executive’s pay during any period of sickness absence is reduced or the Executive is paid SSP only, the level of contributions in respect of the Executive’s membership of the relevant pension scheme may continue at the minimum auto enrolment level (or such other core level notified to you) subject to the relevant pension scheme rules in force at the time of the Executive’s absence.
9.8After absence from work through certificated sickness for fifty two (52) weeks, the Executive may be eligible for extended sick pay (subject to a maximum of five years in total) under the Company’s insured extended sick pay scheme, subject to the rules in force from time to time, including acceptance of the Executive’s claim by the Company’s insurers. Details of extended sick pay are included in the benefits guidebook. The Company reserves the right to replace or withdraw or amend this scheme at any time without providing any replacement on one month’s notice to the Executive.
9.9The Company shall only make payments to the Executive in relation to extended sick pay if it has received payment from the insurance provider for that purpose. If the insurance provider refuses for any reason to provide extended sick pay to the Executive, the Company shall not be liable to
11
Exhibit 10.3 | ||
provide to the Executive any replacement benefit of the same or similar kind or to pay any compensation in lieu of such.
9.10Whilst the Executive is in receipt of any payments arising from extended sick pay, the continuation of some of the Executive’s benefits will be subject to the Company’s sole discretion.
9.11Without limitation to clause 10.4 below, the Company reserves the right to terminate the Executive’s employment by giving written notice should incapability render the Executive unable to undertake the Executive’s duties or as otherwise set out in the sickness absence policy.
9.12The Executive agrees to consent to a medical examination (at the Company's expense) by a doctor nominated by the Company should the Company so require. The Executive agrees that any report produced in connection with any such examination may be disclosed to the Company and the Company may discuss the contents of the report with the relevant doctor.
9.13If a period of sickness absence is or appears to be occasioned by actionable negligence, nuisance or breach of any statutory duty on the part of a third party, in respect of which damages are or may be recoverable, the Executive must immediately notify the Company of that fact and of any claim, compromise, settlement or judgment made or awarded in connection with it and all relevant particulars that the Company may reasonably require. If the Company requires the Executive to do so, the Executive must co-operate in any related legal proceedings and refund to the Company that part of any damages or compensation the Executive recovers that relates to lost earnings for the period of sickness absence as the Company may reasonably determine, less any costs the Executive incurred in connection with the recovery of such damages or compensation, provided that the amount to be refunded to the Company shall not exceed the total amount the Company paid to the Executive in respect of the period of sickness absence.
10.TERMINATION AND NOTICE PERIOD
10.1The prior written notice required from the Executive or the Company to terminate this contract of employment shall be six calendar months’ written notice.
10.2Notwithstanding clause 10.1, the Company may, in its sole and absolute discretion, terminate the Executive’s employment at any time and with immediate effect by notifying the Executive that the Company is exercising its right to make a payment in lieu of notice, as provided for under this clause 10 (“Payment in Lieu”). This Payment in Lieu will be equal to the basic salary and the Flex Fund (as at the date of termination) which the Executive would
12
Exhibit 10.3 | ||
have been entitled to receive under this contract of employment during the applicable notice period referred to at clause 10.1 above (or, if notice has already been given, during the remainder of the notice period) less income tax and national insurance contributions. For the avoidance of doubt, the Payment in Lieu shall not include any element in relation to:
(a)any bonus, ICP or commission payments that might otherwise have been due during the period for which the Payment in Lieu is made;
(b)any awards under the Company’s long-term incentive plans (which shall be governed by the applicable award agreements); and/or
(c)any payment in respect of any holiday entitlement that would have accrued during the period for which the Payment in Lieu is made.
10.3The Company shall be entitled to dismiss the Executive at any time without notice or Payment in Lieu if the Executive commits a fundamental breach of this contract of employment or if the Executive is guilty of gross misconduct, or if the Executive ceases to be entitled to work in the United Kingdom and/or is not able to obtain the necessary security clearance reasonably required by the Company. Where the Company considers that the breach is capable of remedy, the Company shall, where reasonably practicable, give the Executive written notice specifying the breach and a reasonable opportunity (not exceeding 14 days) to remedy it before exercising its right of summary dismissal under this clause.
10.4The rights of the Company to terminate the Executive’s employment under the terms of this contract of employment apply even when such termination would or might cause the Executive to forfeit any entitlement to sick pay, permanent health insurance or other benefits.
11.CONTRACTUAL SEVERANCE PAYMENT
11.1Subject to the conditions set out below, if the Company terminates the Executive's employment for any reason other than (a) lawfully in accordance with a reason entitling the Company to dismiss the Executive without notice under clause 10.3 above, (b) the Executive's resignation (unless in the context of a constructive dismissal claim), or (c) a termination in connection with a change in control for which the Executive receives a severance, separation or termination payment under the Senior Management Severance Agreement which is greater than the Severance Payment (defined below), the Company shall pay the Executive a severance payment equal to the aggregate of (i) twelve months' basic salary at the rate in effect at the date on which the Executive's employment terminates ("Termination Date"), and (ii) an amount equal to 100% of the Executive's ICP Compensation ("Severance Payment"), less income tax and national insurance contributions as the Company reasonably determines are required by law. The Severance
13
Exhibit 10.3 | ||
Payment shall be calculated and paid in accordance with the terms of this contract.
11.2For the purposes of this clause, "ICP Compensation" means: (a) the average annual ICP received by the Executive over the three most recent fiscal years preceding the year in which the Termination Date falls; (b) if the Termination Date occurs before the Executive has completed three fiscal years of employment, the annual ICP received by the Executive in respect of the most recent complete fiscal year preceding the year in which the Termination Date falls; or (c) if the Executive has been employed for less than a single complete fiscal year preceding the year in which the Termination Date falls, the Executive's target annual ICP opportunity.
11.3The Severance Payment is inclusive of any basic salary paid during the Executive's notice period or any Payment in Lieu paid under clauses 10.1 and 10.2 in respect of the same termination. The amount otherwise payable as the Severance Payment shall be reduced on a pound-for-pound basis by the amount of any such basic salary or Payment in Lieu and by any statutory redundancy payment, so that the aggregate amount paid to the Executive in respect of basic salary, notice pay, statutory redundancy pay and the Severance Payment shall equal twelve months' basic salary, together with 100% of the Executive's ICP Compensation.
11.4The Company's obligation to make the Severance Payment is conditional on the Executive: (a) entering into, a settlement agreement in a form required by the Company that includes a full and effective waiver and release of all claims against the Company and each Group Company; (b) complying with, and where requested reaffirming in that settlement agreement, the post-termination restrictions in Appendix 3 and the Executive's continuing confidentiality obligations; and (c) not being, as at the Termination Date, in material breach of this contract of employment, such materiality to be determined by the Company acting reasonably. If any of these conditions are not satisfied, no Severance Payment shall be due.
11.5The Executive shall have no entitlement to a Severance Payment where the Executive is entitled to a severance, separation or termination payment under the Senior Management Severance Agreement in connection with a change in control as referenced in clause 13 below and a payment under the Senior Management Severance Agreement is greater than the Severance Payment. Under no circumstances will the Executive be eligible to receive both the Severance Payment and a payment under the Senior Management Severance Agreement and in the event of a change in control event, the Senior Management Severance Agreement shall apply in place of the above Severance Payment.
14
Exhibit 10.3 | ||
11.6The Severance Payment shall be paid within 30 days after the later of the Termination Date and the date on which the settlement agreement is signed by all parties.
12.GARDEN LEAVE
12.1Following service of notice to terminate this contract of employment by either party, or if the Executive purports to terminate the contract of employment in breach of contract, the Company may by written notice place the Executive on Garden Leave. Any period of Garden Leave shall not normally exceed 6 months.
12.2During any period of Garden Leave:
(a)the Company shall be under no obligation to provide any work to the Executive and may revoke any powers the Executive holds on behalf of any Group Company;
(b)the Company may require the Executive to carry out alternative duties or to only perform such specific duties as are expressly assigned to the Executive, at such location (including the Executive’s home) as the Company may decide;
(c)the Executive shall continue to receive the Executive’s basic salary and all contractual benefits in the usual way and subject to the terms of any benefit arrangement;
(d)the Executive shall remain an Executive of the Company and bound by the terms of this contract of employment (including any implied duties of good faith and fidelity);
(e)the Executive shall ensure that the Executive’s manager knows where the Executive will be and how the Executive can be contacted during each working day (except during any periods taken as holiday in the usual way);
(f)the Company may exclude the Executive from any premises of any Group Company; and
(g)the Company may require the Executive not to contact or deal with (or attempt to contact or deal with) any officer, Executive, consultant, client, customer, supplier, agent, distributor, shareholder, adviser or other business contact of any Group Company.
12.3Upon termination of this contract of employment or where the Executive has been placed on Garden Leave, the Executive shall be required to return all property, including that provided as a contractual benefit, provided to the Executive by the Company for use during this contract of employment and confirm that all of the Group Company’s information has been removed from any of the Executive’s personal devices.
15
Exhibit 10.3 | ||
13.CHANGE IN CONTROL
13.1On or as soon as practicable after the Executive’s first day of employment, the Executive and DXC shall enter into the enclosed DXC Technology Severance Plan for Company Senior Management and Key Employees Severance Agreement (Senior Management Severance Agreement).
14.DISCIPLINARY AND GRIEVANCE POLICIES
14.1The Executive’s attention is drawn to the disciplinary and grievance policies applicable to the Executive’s employment, which are available on the Company’s intranet. These policies do not form part of this contract of employment.
14.2If the Executive wishes to appeal against a disciplinary decision the Executive may apply in writing in accordance with the Company’s disciplinary policy.
14.3The Company reserves the right to suspend the Executive with pay for no longer than is necessary to investigate any allegation of misconduct against the Executive or so long as is otherwise reasonable while any disciplinary policy against the Executive is outstanding.
14.4If the Executive wishes to raise a grievance the Executive may apply in writing in accordance with the Company’s grievance policy.
15.PENSIONS
15.1The Company will comply with the employer pension duties in respect of the Executive in accordance with Part 1 of the Pensions Act 2008 (Pensions Act).
15.2The Executive is eligible to be a member of the relevant DXC defined contribution plan (DC Plan) subject to the rules of the DC Plan from time to time. The Executive will be automatically enrolled into the DC Plan with a default level of contribution at or above the minimum in accordance with the Pensions Act.
15.3Notwithstanding the Company’s statutory obligations in relation to automatic enrolment, the Executive may use the Company’s flexible benefit system to elect to increase the Executive’s pension contribution in accordance with the DC Plan rules. Subject to the terms of the benefits guidebook and the rules of the DC Plan from time to time, the Company will make available funding to
16
Exhibit 10.3 | ||
match the Executive’s contribution on a 1 for 1 matched basis up to a maximum of 6% equivalent of the Executive’s basic salary subject to the scheme cap.
15.4The Executive’s pension contributions will be made through ‘salary sacrifice’ which the Company operates for contributions to the pension scheme through the Company’s benefit scheme site.
15.5Further details of the Company’s pension scheme are available in the benefits guidebook and associated pension scheme materials.
16.COLLECTIVE AGREEMENT
There is no collective agreement which directly affects the Executive’s employment.
17.CONFIDENTIAL INFORMATION
17.1The Executive shall not use or disclose to any person either during or at any time after the Executive’s employment with the Company any Confidential Information or Trade Secrets about the business or affairs of the Company or any of its clients or business contacts, or about any other matters which may come to the Executive’s knowledge in the course of employment. For the purposes of this contract of employment, Confidential Information and Trade Secrets includes but is not limited to personal and/or business information concerning the Company’s Executives (including salary or other personal information) or the business of the Company including but not limited to corporate and marketing strategy, new product development; research and development, business development and business plans, management accounts, financial and management reports, information relating to the financial affairs of the Company, sales reports, business contacts, lists of suppliers and customers and details of contracts with them together with any information or matter which is not in the public domain (except as a result of the Executive’s breach of this contract of employment) and which relates to the affairs of the Company or any of its business contacts.
17.2The restriction in clause 17.1 does not apply to:
(a)prevent the Executive from making a protected disclosure within the meaning of section 43A of the Employment Rights Act 1996; or
(b)use or disclosure that has been authorised by the Company, is required by law or by the Executive’s employment.
18.COMPANY PROPERTY
17
Exhibit 10.3 | ||
18.1All documents, manuals, hardware and software provided for the Executive’s use by the Company, and any data or documents (including copies) produced, maintained or stored on the Company's computer systems or other electronic equipment (including mobile phones), remain the property of the Company.
18.2Any Company property in the Executive’s possession and any original or copy documents obtained by the Executive in the course of the Executive’s employment shall be returned to the Executive’s manager and/or the Executive shall confirm that it has been securely deleted from any personal electronic equipment (including mobile phones) at any time on request and in any event prior to the termination of the Executive’s employment with the Company.
19.DATA PROTECTION
19.1The Executive acknowledges that the Company will need to collect, hold and/or process personal data relating to the Executive in accordance with the Company’s Employee Privacy Notice and Data Protection Policy (as amended from time to time) which are available on the Company’s identified internal Executive communications systems, such as the intranet and other resources as communicated by the Company.
19.2The Executive shall read and at all times comply with the Company’s Employee Privacy Notice and Data Protection Policy and/or any instructions relating to privacy and data protection when handling personal data in the course of employment including personal data relating to any Executive, customer, client, supplier or agent of the Company and/or any Group Company.
19.3The Executive undertakes to take all reasonable steps to ensure that confidential information relating to or belonging to the Company and/or any Group Company or personal data which the Executive accesses, holds or processes during the course of employment will not be available or disclosed to third parties and will be kept securely by the Executive, particularly if such information is accessed by or accessible by the Executive via a mobile device; and immediately notify the Company in accordance with the Company’s incident response process if the Executive becomes aware of any unauthorised disclosures of any confidential information relating to or belonging to the Company or any Group Company or personal data or any other breaches of the Company’s policies .
19.4The Executive acknowledges that the Company makes personal data available to any Group Company, those who provide products or technical and operational services to any Group Company (such as advisers, payroll administrators and system and database administrators), regulatory
18
Exhibit 10.3 | ||
authorities, potential purchasers of the Company or the business in which the Executive works, for legitimate business purposes and as may be required by law.
19.5The Executive acknowledges that the Company may lawfully transfer such information to any Group Company and any Group Company's business contacts, external service providers and contractors within and outside the UK and the European Union in order to further its or their business interests.
19.6The Executive acknowledges that a failure to meet the obligations in clause 19 may lead to disciplinary action up to and including termination under the Company’s Disciplinary Policy
20.CONDUCT
20.1The Executive is required at all times to comply with the Company’s rules, policies and procedures in force from time to time (including, but not limited to, DXC’s code of business conduct and information security policy) including any mandatory training required to meet those policies and procedures which are available on the intranet. Failure to comply with the Company’s rules, policies and procedures may result in disciplinary action up to and including the immediate termination of the Executive’s employment.
20.2The Executive shall not work for anyone else whilst employed by the Company without the Company’s prior written consent.
21.SECURITY AND MONITORING
21.1The Executive acknowledges that, in accordance with the Company’s Employee Privacy Notice and Data Protection Policy (as amended from time to time) which are available on the Company’s identified internal Executive communications systems, such as the intranet and other resources as communicated by the Company, the Company performs monitoring and recording of its Executive’s electronic communications systems for the purpose of ensuring that the Group Company’s rules are being complied with and for legitimate business purposes. The Executive is required to comply with any electronic communication systems policies that the Company may issue from time to time.
21.2The Executive agrees that security staff have a right to ask employees to open any bag, container or vehicle being brought onto or taken off any Group Company, client or supplier site. Failure to permit a search without reasonable cause may result in disciplinary action.
22.TRAINING
19
Exhibit 10.3 | ||
22.1During your employment:
(a)you must complete:
(i)the induction training;
(ii)the annual training related to ethics and compliance, security, privacy and data protection; and
(iii)the annual security awareness training.
(in a format set out by the Company from time to time) which will be paid for by the Company; and
(b)you are entitled to take part in various training courses which we may provide from time to time which can be found on the DXC University intranet site.
23.INTELLECTUAL PROPERTY
23.1The Executive shall give the Company full written details of all Inventions and of all works embodying Intellectual Property Rights made wholly or partially by it at any time during the course of the employment which relate to, or are reasonably capable of being used in, the business of any Group Company. The Executive acknowledges that all Intellectual Property Rights subsisting (or which may in the future subsist) in all such Inventions and works shall automatically, on creation, vest in the Company absolutely. To the extent that they do not vest automatically, the Executive holds them on trust for the Company. The Executive agrees promptly to execute all documents and do all acts as may, in the opinion of the Company, be necessary to give effect to this clause 23.1.
23.2The Executive hereby irrevocably waives all moral rights under the Copyright, Designs and Patents Act 1988 (and all similar rights in other jurisdictions) which he has or will have in any existing or future works referred to in clause 23.1.
23.3Should the Company request, the Executive agrees to appoint, and execute any necessary documents required to appoint, the Company to be the Executive’s attorney in the Executive’s name and on the Executive’s behalf to execute documents, use the Executive’s name and do all things which are necessary or desirable for the Company to obtain for itself or its nominee the full benefit of this clause.
24.ANTI-CORRUPTION AND BRIBERY CLAUSE
24.1The Company takes a zero-tolerance approach to bribery and corruption. The Executive must comply with the Company’s anti-corruption and bribery policy,
20
Exhibit 10.3 | ||
the code of business conduct and related procedures, a copy of which is available on the intranet at all times. Failure to do so will be treated as a disciplinary matter and may result in disciplinary action up to and including the immediate termination of the Executive’s employment.
25.THIRD PARTY RIGHTS
No one other than the Executive and the Company (or any Group Company) shall have any right to enforce any terms of this contract of employment.
26.POST-TERMINATION RESTRICTIONS
26.1The provisions in the attached Appendix 3 shall apply. For the purposes of Appendix 3, "DXC" means the Company, and each Group Company may enforce Appendix 3 in accordance with clause 25.
27.CLAWBACK AND RECOUPMENT OF INCENTIVE COMPENSATION
27.1The Executive acknowledges and agrees that any incentive compensation paid or awarded to the Executive (including, without limitation, ICP payments, LTI awards, RSU awards, and any other performance-based or equity-based compensation) shall be subject to clawback and recoupment by the Company in the following circumstances:
(a)Financial restatement: If the Company is required to prepare a material accounting restatement of its financial statements due to material noncompliance with any financial reporting requirement under applicable securities laws, the Company may recover from the Executive any incentive compensation received during the three-year period preceding the date on which the Company is required to prepare such restatement that exceeds the amount that would have been paid to the Executive based on the restated financial results;
(b)Misconduct: If the Executive engages in fraud, wilful misconduct, or a material breach of this contract of employment or any Group Company policy (including, without limitation, the DXC Code of Business Conduct), the Company may recover all or part of any incentive compensation paid or awarded to the Executive during the period in which the misconduct occurred and the 12 months following discovery of such misconduct;
(c)Breach of restrictive covenants: If the Executive materially breaches any of the post-termination restrictions in Appendix 3, the Company may recover all or part of any incentive compensation paid to the Executive in the 12 months preceding the date of termination and any unvested awards shall be forfeited.
21
Exhibit 10.3 | ||
27.2The Executive further acknowledges that:
(a)all incentive compensation is subject to any clawback or recoupment policy adopted by DXC Technology Company from time to time, including any policy required by the U.S. Securities and Exchange Commission, the New York Stock Exchange, or any other applicable regulatory authority. In the event of any conflict between this clause and such policy, the terms most favourable to the Company shall prevail; and
(b)pursuant to SEC Rule 10D-1 and applicable NYSE listing standards, DXC Technology Company is prohibited from indemnifying or insuring the Executive against the loss of any erroneously awarded incentive-based compensation that is required to be recovered under DXC's Compensation Recovery Policy. No provision of this contract shall be construed to limit or modify DXC's right and obligation to recover such compensation.
27.3The Company may effect any recovery under this clause by (a) requiring direct repayment from the Executive, (b) set-off against any amounts otherwise payable to the Executive (subject to applicable law), or (c) cancellation or forfeiture of outstanding unvested awards. The Company shall provide the Executive with reasonable written notice of its intention to exercise clawback rights under this clause.
28.DIRECTORS' AND OFFICERS' INSURANCE AND INDEMNIFICATION
28.1Throughout the Executive's employment and for a period of six years following termination of employment (howsoever arising), the Company shall procure that the Executive is covered under DXC Technology Company's directors' and officers' liability insurance policy on terms no less favourable than those provided to other senior officers of DXC Technology Company.
29.CONFLICTS OF INTEREST AND OUTSIDE ACTIVITIES
29.1During the term of employment, the Executive shall not, without the prior written consent of the Chief Executive Officer:
(a)hold any directorship, office, or employment with any company, business, or organisation other than the Company or a Group Company;
(b)engage in any business activity that conflicts with, or could reasonably be expected to conflict with, the interests of the Company or any Group Company; or
22
Exhibit 10.3 | ||
(c)acquire any financial interest (other than holdings of not more than 5% of the issued share capital of any publicly listed company) in any supplier, customer, competitor, or business partner of the Company or any Group Company.
29.2The Executive shall promptly disclose to the Chief Executive Officer or the Chief People Officer any situation that may give rise to an actual or potential conflict of interest and shall complete a Conflict of Interest questionnaire on or prior to his employment commencing.
30.SECTION 16 OFFICER
30.1The Executive acknowledges that, by virtue of his position, the Executive is or will become a "Section 16 officer" of DXC Technology Company as defined under Section 16 of the U.S. Securities Exchange Act of 1934.
30.2The Executive agrees to:
(a)comply with DXC Technology Company's Insider Trading Policy (as amended from time to time);
(b)not purchase or sell DXC securities during blackout periods or without obtaining pre-clearance as required by such policies;
(c)promptly report all transactions in DXC securities to enable timely filing of SEC Forms 3, 4, and 5;
(d)not engage in any hedging transaction (including prepaid variable forwards, equity swaps, collars, or exchange funds) or pledge DXC securities as collateral; and
(e)acknowledge that any profit realized from a purchase and sale, or sale and purchase, of DXC equity securities within any period of less than six months is recoverable by DXC Technology Company under Section 16(b) of the Exchange Act.
30.3The Executive shall cooperate with DXC Technology Company in connection with all SEC filing and disclosure obligations, including providing information reasonably required for proxy statements, annual reports, and current reports, and reviewing and approving disclosure relating to the Executive's compensation and biographical information within reasonable timescales.
31.ENTIRE AGREEMENT
31.1This contract of employment constitutes the entire agreement between the parties and supersedes and extinguishes all previous agreements, promises, assurances, warranties, representations and understandings between them, whether written or oral, relating to its subject matter, but excluding any equity arrangements which shall be separately documented.
23
Exhibit 10.3 | ||
31.2Each party acknowledges that in entering into this contract of employment it does not rely on, and shall have no remedies in respect of, any statement, representation, assurance or warranty (whether made innocently or negligently) that is not set out in this contract of employment.
31.3Each party agrees that it shall have no claim for innocent or negligent misrepresentation or negligent misstatement based on any statement in this contract of employment.
31.4Nothing in this clause shall limit or exclude any liability for fraud.
32.CONSTRUCTION
32.1The clauses and sub-clauses of this contract of employment shall be read and constructed independently of each other. Any invalidity of any such clause or sub-clause shall not affect the remaining clauses or sub-clauses.
33.COUNTERPARTS
33.1This contract of employment may be executed in any number of counterparts, each of which when executed and delivered shall constitute a duplicate original, but all the counterparts shall together constitute one agreement.
34.GOVERNING LAW AND JURISDICTION
34.1This contract of employment and any dispute or claim arising out of or in connection with it or its subject matter or formation (including non-contractual disputes or claims) shall be governed by and construed in accordance with the law of England and Wales.
34.2Each party irrevocably agrees that the courts of England and Wales shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this contract of employment or its subject matter or formation (including non-contractual disputes or claims).
34.3This contract of employment has been executed as a deed and is delivered and takes effect once signed as a deed by the Executive.
24
Exhibit 10.3 | ||
Jennifer Ragone Chief People Officer | ||
IN WITNESS whereof the Executive executes this contract of employment as a deed on the day and year first above written. SIGNED AS A DEED } By PAUL TAYLOR } in the presence of: Witness’ Name [***] Address [***] | ||
Appendix 1: Definitions
Garden Leave: any period during which the Company has exercised its rights under clause 12.
Group Company: the Company, its Subsidiaries and Holding Companies from time to time and any Subsidiary of any Holding Company from time to time.
Intellectual Property Rights: patents, rights to Inventions, copyright and related rights, trade marks, trade names and domain names, rights in get-up, goodwill and the right to sue for passing off or unfair competition, rights in designs, rights in computer software, database rights, rights to preserve the confidentiality of information (including know-how and trade secrets) and any other intellectual property rights, in each case whether registered or unregistered and including all applications (or rights to apply) for and be granted, renewals or extensions of, and rights to claim priority from, such rights and all similar or equivalent rights or forms of protection which may now or in the future subsist in any part of the world.
Inventions: inventions, ideas and improvements, whether or not patentable, and whether or not recorded in any medium.
Subsidiary and Holding Company: in relation to a company mean "subsidiary" and "holding company" as defined in section 1159 of the Companies Act 2006 and a company shall be treated, for the purposes only of the membership requirement contained in subsections 1159(1)(b) and (c), as a member of another company even if its shares in that other company are registered in the name of (a) another person (or its nominee), whether by way of security or in connection with the taking of security, or
(b) a nominee.
SSP: statutory sick pay
25
Exhibit 10.3 | ||
26

Appendix 2: Additional Entitlements
In addition to the salary and benefits package set out in clause 4 of the contract of employment the Executive will also be entitled to the following:
CAR AND DRIVER
The Company will provide the Executive with a Company-arranged car and driver for use in and around London for business travel required for the proper performance of the Executive's duties. The car and driver are provided for Company business use only. Any use of the car and/or driver for ordinary commuting or for private purposes shall be treated as a taxable benefit in kind, which the Company will report to HM Revenue & Customs (and on which the Company will account for employer Class 1A National Insurance contributions), with the Executive bearing the associated personal income tax. The car and driver are provided subject to the Company's travel policies (as amended from time to time), which do not form part of this contract of employment. This benefit is provided in place of, and not in addition to, any cash car allowance.
COMPANY AIRCRAFT
From the commencement of employment, the Executive shall be eligible to use Company Aircraft (including the Company's NetJets fractional-interest aircraft) for Business Use, subject to and in accordance with the DXC Technology Company Aircraft Use Policy (as amended from time to time) (Aircraft Use Policy). All use of Company Aircraft is subject to authorisation by the Chief Executive Officer or his or her designee in accordance with the Aircraft Use Policy, and to the priority, scheduling, safety and reporting procedures set out in that policy. Use is limited to Business Use as defined in the Aircraft Use Policy; any Non-Business Use is subject to the restrictions, authorisation requirements and tax-reporting provisions of the Aircraft Use Policy. The Aircraft Use Policy does not form part of this contract of employment.
IN LIEU CASH ALLOWANCE
In recognition of the restrictions on tax-relieved pension saving that apply to the Executive as a result of the statutory tapered annual allowance, the Company will pay the Executive a cash allowance of £25,000 per annum in lieu of additional employer pension contributions. This allowance will be paid in equal monthly instalments through payroll, subject to deductions for income tax and National Insurance contributions. The allowance is non-pensionable and shall be excluded from the calculation of any other element of the Executive's remuneration or benefits, including any bonus, ICP, long-term incentive, severance or other termination payment. There is no requirement on the Company to increase this amount in the future. The company car policy and travel expense policy will be applicable to the Executive at all times.
25

INCENTIVE COMPENSATION PLAN (ICP)
The Executive will be eligible to participate in the FY27 ICP (Fiscal year runs 1st of April, 2026 to 31st of March 2027), and the target incentive opportunity will be 200% of annual basic salary, pro-rated as appropriate based on the Executive’s start date, if after the beginning of the fiscal year. The Executive’s earned ICP award, if any, will be based on both Company and individual performance and will be payable in cash in accordance with the terms of the DXC ICP Operating Rules.
RSU INDUCEMENT AWARD
The Executive will be granted a one-time inducement grant with a target value of $3,750,000.00 USD and an equity mix of 60% Performance Stock Units (“PSU”) and 40% Restricted Stock Units (“RSU”). This inducement award will be made in accordance with and subject to the terms of DXC’s Equity Grant Policy, applicable award agreements, plans and related policies, on the 15th of the month following the month in which the grant is approved, as follows:
| Award | LTI Mix | Value | Vesting | ||||||||
Inducement Grant | 60% PSUs/ 40% RSUs | $3,750,000.00 USD | PSUs: Vest between 0% and 200% based 50% on cumulative Free Cash Flow performance and 50% on cumulative Revenue performance, with a +/- 20% relative Total Shareholder Return modifier, over a 3-year performance period (April 1, 2026 – March 31, 2029), subject to the Executive’s continued employment with DXC through the end of the performance period. For the avoidance of doubt, the vesting terms reflect the same PSU design and financial targets as the FY27 annual cycle PSUs. RSUs: Vests in equal thirds on the 1st, 2nd, and 3rd anniversaries of the grant date, subject to the Executive’s continued employment with DXC on each vesting date. | ||||||||
Note: The approved value of the award will be converted to PSUs and RSUs in accordance with DXC Technology’s Equity Grant Policy. The specific terms and conditions that govern all awards will be set forth in the applicable award agreement, plan, and policies. All equity awards are subject to the approval of the Compensation Committee of DXC Technology’s Board of Directors, or such other Committee of the Board designated by the Compensation Committee. | |||||||||||
26

LONG-TERM INCENTIVES (LTI)
The Executive will receive a long-term incentive annual award for FY27 (April 1, 2026, to March 31, 2027) with a target value of 900% of annual basic salary. This LTI award will be prorated based on the full calendar months between the Executive’s start date of employment with DXC and the end of FY27. For the avoidance of doubt, with an assumed start date in August 2026, this LTI award will be prorated for 7 full calendar months of service in FY27, with a target value of $5,250,000.00 USD. This LTI award will be made to the Executive on the 15th of the month following the month of his employment start date. All LTI awards will be made in accordance with and subject to the terms of DXC’s Equity Grant Policy, applicable award agreements, plans and related policies. LTI awards will be subject to DXC continuing to maintain such a Long-Term Incentive program in effect. In subsequent years, the Executive will continue to be eligible for LTI each fiscal year, subject to the eligibility requirements for each year and his and DXC’s performance, provided that DXC Technology continues to maintain such an LTI program in effect.
Prior to the date of grant of each New Hire LTI Award, the Company shall provide the Executive with a copy of the applicable Award Agreement. The Company warrants that the terms of each such Award Agreement shall be consistent with and shall give effect to the Approved Termination treatment set out in this Appendix 2
The Company warrants that, save as set out in Clause 27 of this contract of employment, the applicable Award Agreements do not contain any additional clawback, recoupment or forfeiture provisions triggered by the Executive's conduct, departure, or breach of restrictive covenants beyond those expressly set out in this contract.
EFFECT OF TERMINATION OF EMPLOYMENT ON INDUCEMENT AWARD AND FY27 LTI ANNUAL AWARD ("NEW HIRE LTI AWARDS")
If the Company terminates the Executive's employment for any reason other than (a) a reason entitling the Company to dismiss the Executive for Cause as defined in the applicable Award Agreements, (b) the Executive's resignation, or (c) a termination in connection with a change in control, then such termination shall for all purposes be treated as an "Approved Termination" as defined in Section 3(a)(ii) of DXC's PSU and RSU award agreements.
On such an Approved Termination, the Executive's Performance-Based Restricted Stock Units and Restricted Stock Units under the New Hire LTI Awards shall vest and settle on a pro-rata, time-served basis (which shall expressly include any period spent on Garden Leave) in accordance with, and calculated as provided in, Section 3(a) of the applicable award agreements. For the avoidance of doubt, the Performance-Based Restricted Stock Units shall remain subject to actual performance over the full performance period and shall settle on the Scheduled Settlement Date determined under the applicable award agreement, and no acceleration to target shall apply.
27

This treatment applies only to the New Hire LTI Awards. All equity awards granted to the Executive in respect of FY28 and any subsequent fiscal year shall be governed solely by the standard terms of the applicable DXC award agreements, plan and policies then in effect.
In the event of a Change in Control in which the New Hire LTI Awards are assumed or substituted by the acquiring entity, the Executive shall, on a qualifying termination of employment within 24 months following such Change in Control, be entitled to full vesting of all outstanding New Hire LTI Awards (with any outstanding PSUs vesting at target level of performance), to the extent not already provided for under the terms of the Senior Management Severance Agreement.
TAX PREPARATION AND FILING ASSISTANCE
Where the Executive incurs personal tax filing obligations in more than one jurisdiction as a direct result of duties, travel or work locations directed or required by the Company, the Company will, for the duration of the Executive's employment and post-termination for all tax years still requiring reporting in respect of the Executive's employment earnings or post-termination earnings from this employment, reimburse the reasonable cost of professional tax preparation and filing services in respect of those obligations, on production of valid invoices. It is currently estimated that such costs will be in the region of £25,000 to £35,000 per annum; this is an estimate only and not a cap or a guaranteed amount. This benefit applies only to filing obligations arising from Company-directed multi-jurisdiction work and does not extend to the Executive's personal tax affairs generally.
28

Appendix 3
NON-COMPETITION/NON-SOLICITATION AGREEMENT – UNITED KINGDOM
Introduction and ConsiderationThis Non-Competition/Non-Solicitation Agreement (the “Agreement”) is made between Paul Taylor (the “Executive”) AND EntServ UK Limited, (a DXC Technology company) (“DXC”). The Executive acknowledges that (i) each DXC Group member participates in and conducts business on behalf of the international business of DXC under the holding company, namely DXC Technology Company, and each member of the DXC Group has a legitimate interest in protecting the business of the DXC Group, its trade connections, and the stability of its workforce, and (ii) DXC is in a competitive industry in which the creation, maintenance and use of trade secrets, confidential and proprietary information are critical to business success, and that the protection of that information is a legitimate business interest of DXC. Notwithstanding the commonly held business interests across the DXC Group, the Executive, at the request and cost of DXC, shall enter into a separate non-competition/non-solicitation agreement for the benefit of any other member of the DXC Group. If the Executive fails, within 7 days of receiving such a request from DXC, to sign the necessary documents to give effect to the foregoing, DXC will be entitled, and is hereby irrevocably and unconditionally authorised by the Executive, to execute all such documents as are required to give effect to the foregoing, on his behalf. The Executive also acknowledges that this Agreement is reasonably necessary to protect the goodwill and other legitimate business interests of DXC.
II
DefinitionsFor this Appendix 3 the following definitions shall apply:
“DXC Group” means the group of companies composed of DXC Technology Company (the "Holding Company") and all Subsidiary Companies of the Holding Company, where "Holding Company" and "Subsidiary Company" shall have the meanings respectively attributed to them in the Companies Act 2006, Section 1159.
“Employer Business” means the business of providing technology-enabled solutions, products and services on an international basis, including system design and integration, information technology and business process outsourcing, applications software development, proprietary software sales and implementations, Web and application hosting, mission support and management consulting.
"Client" means any person, firm, company or other organisation whatsoever to whom DXC or another member of the DXC Group has supplied goods or services and (1) with whom the Executive has had material contact or dealings on behalf of DXC during the 12 months immediately prior to the Termination Date or (2) for whom they were, in a client management capacity on behalf of DXC, directly responsible in
29

the 12 months prior to the Termination Date.
“Confidential Information” means all DXC trade secrets, patents, copyrights, confidential or proprietary business information, skill and knowledge not publicly available, particular to the Employer Business and gained by the Executive solely as a result of and during the course of employment with DXC, and sales and financial data, pricing information, manufacturing and distribution methods, information relating to DXC’s business plans and strategies including, but not limited to, Restricted Persons, vendors, customers and/or prospects, or lists thereof, marketing plans and procedures, research and development plans, methods of doing business, both technical and non-technical, information relating to the design, architecture, flowcharts, source or object code and documentation of any and all computer software products which DXC has developed, acquired or licensed or is in the process of developing, acquiring or licensing or shall develop, acquire or license in the future, hardware and database technologies or technological information, formulae, designs, process and systems information, intellectual property rights, and any other confidential or proprietary information which relates to the business of DXC or to the business of any client or vendor of DXC or any other party and provided to DXC in confidence, whether patentable, copyrightable or protectable as trade secrets or not. Confidential Information does not include information which is (i) already known by Executive without an obligation of confidentiality, (ii) publicly known or becomes publicly known through no unauthorized act of Executive or any other person, (iii) rightfully received from a third party without an obligation of confidentiality, (iv) disclosed without similar restrictions by DXC to a third party (other than an affiliate or customer of DXC), or
(v) approved by DXC, in writing, for disclosure.
"Garden Leave" means any period of time during which the Executive remains an Executive of DXC but is under notice and is not required to attend at work or undertake any work, and is also required by DXC not to contact any customers, suppliers, officers, Executives, consultants, agents, distributors, shareholders, advisers or business contacts of DXC or any DXC Group Member, or undertake any work on behalf of DXC or any DXC Group Member, unless on the express instruction of, or with the prior consent of, DXC.
"Prospective Client" means any person, firm, company or other organisation with whom any company in the DXC Group has had any negotiations or material discussions regarding the possible supply of goods or services by that DXC Group company.
“Restricted Business” means those parts of the Employer Business with which the Executive was involved to a material extent in the 12 months prior to the termination of the Executive’s employment or commencement of Garden Leave, whichever is the earlier.
“Restricted Period” means the period of: (a) 9 months following the termination of the Executive’s employment, or such lesser period following such termination as, together with the duration of any time spend by the Executive on Garden Leave,
30

equates to an aggregate period of 9 months, in respect of the restrictions in III 2; and (b) 12 months following the termination of the Executive’s employment, or such lesser period following such termination as, together with the duration of any time spend by the Executive on Garden Leave, equates to an aggregate period of 12 months, in respect of the restrictions in III 3, 4 and 5;
“Restricted Person” means anyone employed by DXC or any DXC Group member at the level of Vice President or above or who could materially damage the interests of DXC or DXC Group member if they were involved in any business concern competing with the Restricted Business and with whom the Executive dealt in the course of employment in the 12 months prior to the termination of the Executive's employment or commencement of Garden Leave, whichever is the earlier;
"Supplier" means any person, company, business entity or other organisation whatsoever who:
(a)has supplied goods or services to any company in the DXC Group in the 12 months prior to the termination of the Executive's employment or commencement of Garden Leave, whichever is the earlier; or
(b)has agreed prior to the Termination Date to supply goods or services to any company in the DXC Group to commence at any time in the 12 months prior to the termination of the Executive's employment or commencement of Garden Leave, whichever is the earlier; or
(c)as at the Termination Date, supplies goods or services to any company in the DXC Group under an exclusive contract or arrangement between that Supplier and that DXC Group company.
“Termination Date” means the date upon which the Executive’s employment with DXC ends.
III
Covenants and Related Provisions1.Non-Disclosure and Non-Use of Confidential Information
DXC shall provide the Executive with Confidential Information relating to DXC, its business and clients. The Executive agrees not to disclose, use, copy or duplicate or otherwise permit the use, disclosure, copying or duplication of any Confidential Information (other than in connection with authorized activities conducted in the course of the Executive’s employment with DXC for the benefit of DXC) during or following his/her employment with DXC, without limitation in time. The Executive agrees to take all reasonable steps and precautions to prevent any unauthorized disclosure, use, copying or duplication of Confidential Information.
2.Non-Competition
The Executive agrees that they will not (without the consent in writing of DXC) for the Restricted Period and whether on their own behalf or in conjunction with or on behalf of any other person, firm, company or other organisation, and whether as an Executive, director, principal, agent, consultant or in any other capacity
31

whatsoever, in competition with DXC be directly or indirectly (i) employed or engaged in, or (ii) perform services in respect of, or (iii) be otherwise concerned with:-
2.1.the research into, development, manufacture, supply or marketing of any product which is of the same or similar type to any product researched, or developed, or manufactured, or supplied, or marketed by DXC during the twelve months immediately preceding the Termination Date;
2.2.the development or provision of any services (including but not limited to technical and product support, or consultancy or customer services) which are of the same or similar type to any services provided by DXC during the twelve months immediately preceding the Termination Date;
PROVIDED ALWAYS that the provisions of this paragraph 2 will apply only in respect of the Restricted Business and shall not prohibit the Executive from working in private equity or from undertaking a role as a non-executive director of any company which does not carry on the Restricted Business, following the Termination Date.
3.Non-Dealing with, and Non-Solicitation of, Clients and Prospective Clients The Executive agrees that during the Restricted Period, directly or indirectly, and whether on their own behalf or in conjunction with or on behalf of any person, company, business entity or other organisation (and whether as an Executive, director, principal, agent, consultant or in any other capacity whatsoever), they will not (i) solicit or, (ii) assist in soliciting, or (iii) accept, or (iv) facilitate the acceptance of, or (v) deal with, in competition with any company in the DXC Group, the custom or business of any Client or Prospective Client.
4.Non-Solicitation of Executives
The Executive agrees that they will not during the Restricted Period directly or indirectly either on their own behalf or in conjunction with or on behalf of any other person, company, business entity, or other organisation (and whether as an Executive, principal, agent, consultant or in any other capacity whatsoever):-
4.1.(i) entice, or (ii) induce, or (iii) encourage, or (iv) solicit, any Restricted Person to leave or seek to leave any company in the DXC Group ; or
4.2.be personally involved to a material extent in (i) accepting into employment or (ii) otherwise engaging or using the services of, any person who is a Restricted Person.
5.Non-Employment with Clients, Prospective Clients and Suppliers
The Executive agrees that they will not during the Restricted Period seek or accept employment or a consultancy agreement or any other form of engagement under which they provide services to any person, company, business entity, or other organisation which was, at any time during the twelve months immediately preceding the Termination Date, a Client or Prospective Client or Supplier of any company in the DXC Group:-
32

5.1.with whom they had material contact or dealings on behalf of that DXC Group company; or about whom they had obtained specific Confidential Information as a result of their employment with DXC, and where they would be required to use that Confidential Information in the course of their employment with that Client or Prospective Client or Supplier.
6.Exclusions
None of the restrictions in III 2, 3, 4 and 5 above shall prevent the Executive from holding an investment by way of shares or other securities of less than 5% of the total issued share capital of any company (whether or not a publicly traded corporation) or from being engaged or concerned in any business concern provided that the Executive’s duties or work shall relate solely to services, products or activities of a kind with which the Executive was not concerned to a material extent in the 12 months prior to termination of the Executive’s employment.
7.Injunctive Relief/Remedies
The Executive acknowledges and agrees that if the Executive were to breach, or threaten to breach, any provision of this Agreement, DXC would suffer immediate and irreparable harm and would therefore be entitled to injunctive relief ordered by a court of appropriate jurisdiction. This Paragraph shall not, however, diminish the right of DXC to claim and recover money damages or any other available remedy in addition to injunctive relief.
8.Severability, and Survival
Each provision of this Agreement will be interpreted in such a manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision, to the extent of such prohibition or invalidity, shall be deemed not to be a part of this Agreement, and shall not invalidate the remainder of such provision or the remaining provisions of this Agreement. The Executive specifically agrees that Paragraph III 1 (Non-Disclosure and Non-Use of Confidential Information), Paragraph 2 (Non-Competition), Paragraph III 3 (Non-Dealings with Clients, and Prospective Clients), Paragraph III 4 (Non-Solicitation of Executives) and Paragraph III 5 Non-Employment with Clients, Prospective Clients and Suppliers and each of their provisions, subparagraphs and subparts, are independent of and severable from each other, and may be enforced independently.
9.Waiver of Breach
Any failure or delay on the part of either party to exercise any remedy or right under this Agreement shall not operate as a waiver. The failure of either party to require performance of any of the terms, covenants, or provisions of this Agreement by the other party shall not constitute a waiver of any of the rights under the Agreement. No forbearance by either party to exercise any rights or privileges under this Agreement shall be construed as a waiver, but all rights and privileges shall continue in effect as if no forbearance had occurred. No covenant
33

or condition of this Agreement may be waived except by the written consent of the waiving party.
10.Binding Effect
The Executive agrees that this Agreement shall be binding upon the Executive’s heirs, executors, and other legal representatives or assigns.
11.Amendment
This Agreement may not be modified or amended except by a written instrument executed as a deed by the Executive and DXC’s General Counsel.
12.Entire Agreement
This Agreement constitutes the Executive's and DXC’s entire agreement in relation to the subject matter contained herein only and supersedes all other prior agreements, understandings or representations by or between the parties, whether oral or written, with respect to the specific subject matters herein.
13.Governing Law
This Agreement shall be governed by, and construed in accordance with, the laws of England.
SIGNED AS A DEED }
by PAUL TAYLOR }
in the presence of:
Witness’ Name: [***]
Address: [***]
Appendix 4
Agreement to Opt Out of the 48-Hour Working Week
1.1By signing below, the Executive confirms that the 48-hour weekly working time limit does not apply to him. This limit is set out in the Working Time Regulations 1998 and is based on an average over a rolling 17-week period.
1.2This opt-out takes effect from the date it is signed and continues until the Executive cancels it or his employment with the Company ends.
1.3The Executive acknowledges that he is signing this opt-out freely, and nobody at the Company has pressured or encouraged him to sign, and he has had the chance to take independent advice.
34

1.4The Executive has the right to cancel this opt-out at any time by giving the Company at least four weeks' written notice. Any cancellation should be in writing (including email) and sent to the People & Culture team via DXC Employee Connect.
1.5The Company's duty to protect the Executive’s health and safety is not affected by this opt-out.
1.6The Company will keep a record of this opt-out in line with the Working Time Regulations and its data retention policy.
1.7This opt-out only applies to the 48-hour weekly limit. All other rights under the Working Time Regulations, including rest breaks and annual leave, are unaffected.
The Executive confirms that he has read and understands this opt-out.
Signed: /s/ Paul Taylor
Print Name: Paul Taylor
Job Title: EVP, President Global Offerings and Markets
Date: 29th June 2026
35
Exhibit 31.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Raul Fernandez, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of DXC Technology Company;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
| Date: | October 29, 2026 | /s/ Raul Fernandez | ||||||||||||
| Raul Fernandez Chief Executive Officer | ||||||||||||||
Exhibit 31.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Rob Del Bene, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of DXC Technology Company;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
| Date: | October 29, 2026 | /s/ Rob Del Bene | ||||||||||||
| Rob Del Bene Executive Vice President and Chief Financial Officer | ||||||||||||||
Exhibit 32.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Raul Fernandez, Chief Executive Officer of DXC Technology Company (the "Company"), hereby certify that, to my knowledge:
(1)The Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2026 (the "Report") fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Dated: | October 29, 2026 | /s/ Raul Fernandez | |||||||||
| Raul Fernandez Chief Executive Officer | |||||||||||
Exhibit 32.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Rob Del Bene, Executive Vice President and Chief Financial Officer of DXC Technology Company (the "Company"), hereby certify that, to my knowledge:
(1)The Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2026 (the "Report") fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Dated: | October 29, 2026 | /s/ Rob Del Bene | |||||||||
| Rob Del Bene Executive Vice President and Chief Financial Officer | |||||||||||